Streptavidin-binding peptides and uses thereof by Keefe, Anthony D. et al.
(12) United States Patent (io) Patent No.: US 7,138,253 B2 
Szostak et al. (45) Date of Patent: Nov. 21,2006 
(54) STREPTAVIDIN-BINDING PEPTIDES AND 
USES THEREOF 
(75) Inventors: Jack W. Szostak, Boston, MA (US); 
David S. Wilson, Hayward, CA (US); 
Anthony D. Keefe, Cambridge, MA 
(US) 
(73) Assignee: The General Hospital Corporation, 
Boston, MA (US) 
Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 0 days. 
( * ) Notice: 
(21) Appl. No.: 10/975,582 
(22) Filed: Oct. 28, 2004 
(65) Prior Publication Data 
Sep. 1, 2005 
Related U.S. Application Data 
US 200510191722 A1 
(62) 
(60) 
Division of application No. 101004,381, filed on Oct. 
31, 2001, now Pat. No. 6,841,359. 
Provisional application No. 601244,541, filed on Oct. 
31, 2000. 
(51) Int. C1. 
(52) U.S. C1. ..................................................... 435/69.1 
(58) Field of Classification Search ................ 5301350; 
514112; 435169.1 
Cl2P 21/06 (2006.01) 
See application file for complete search history. 
(56) References Cited 
U.S. PATENT DOCUMENTS 
5,506,121 A 4/1996 Skerra et al. 
5,821,047 A 10/1998 Garrard et al. 
6,103,493 A 8/2000 Skerra et al. 
6,326,157 B1 12/2001 Nolan et al. 
FOREIGN PATENT DOCUMENTS 
wo WO 98/31700 7/1998 
OTHER PUBLICATIONS 
Bayer et al., “Postsecretory Modifications Of Streptavidin,” 
Biochem. J.  259(2):369-376 (1989). 
Caparon et al., “Analysis of Novel Streptavidin-Binding Peptides, 
Identified Using a Phage Display Library, Shows That Amino Acids 
External to a Perfectly Conserved Consensus Sequence and to the 
Presented Peptides Contribute to Binding,” Molecular Diversity 
l(4) :24 1 -246 ( 1995). 
Cho et al., “Constructing High Complexity Synthetic Libraries of 
Long ORFs Using In Etro Selection,” J.  Mol. Biol. 297:309-319 
Clackson and Wells “Zn Etro Selection From Protein and Peptide 
Libraries,” TZBTECH. 12:173-184 (1994). 
Devlin et al., “Random Peptide Libraries: A Source of Specific 
Protein Binding Molecules,” Science 249(4967):404-406 (1990). 
Giebel et al., “Screening of Cyclic Peptide Phage Libraries Identi- 
fies Ligands That Bind Streptavidin With High Affinities,” Biochem- 
istry 34(47):15430-15435 (1995). 
(2000). 
Haeuptle et al., “Binding Sites for Lactogenic and Somatogenic 
Hormones From Rabbit Mammary Gland and Liver,” J.  Biol. Chem. 
258(1):305-314 (1983). 
Katz et al., “Topochemical Catalysis Achieved by Structure-Based 
Ligand Design,” J .  Biol. Chem. 270(52):31210-31218 (1995). 
Katz and Cass, “In Crystals of Complexes of Streptavidin With 
Peptide Ligands Containing the HPQ Sequence the pK, of the 
Peptide Histidine is Less Than 3.0,”J. Biol. Chem. 272(20):13220- 
13228 (1997). 
Katz, B.A., “Stmctural and Mechanistic Determinants of Affinity 
and Specificity of Ligands Discovered or Engineered by Phage 
Display,” Annu. Rev Biophys. Biomol. Struct. 26:27-45 (1997). 
Katz, B.A., “Streptavidin-Binding and -Dimerizing Ligands Dis- 
covered by Phage Display, Topochemistry, and Stmcture-Based 
Design,” Biomol. Eng. 16(1-4):57-65 (1999). 
Katz, B.A., “Binding to Protein Targets of Peptidic Leads Discov- 
ered by Phage Display: Crystal Stmctures of Streptavidin-Bound 
Linear and Cyclic Peptide Ligands Containing the HPQ Sequence,” 
Biochemistry 34(47): 1542 1-15429 (1995). 
Kay et al., “An M13 Phage Library Displaying Random 38-Amino- 
Acid Peptides as a Source of Novel Sequences With Affinity to 
Selected Targets,” Gene 128(1):59-65 (1993). 
Keefe and Szostak, “ATP-Binding Proteins Selected From a Ran- 
dom-Sequence Polypeptide Library,” The Protein Society, Four- 
teenth Symposium, Program and Abstracts, 9(Suppl. 1): 19 & 84 
(No. 184-T), San Diego, CA (2000). 
Lam et al., “A New Type of Synthetic Peptide Library for Identi- 
fying Ligand-Binding Activity,” Nature 354(6348):82-84 (1991). 
Liu et al., “Optimized Synthesis of RNA-Protein Fusions for In 
Etro Protein Selection,” Methods Enzymol. 3 18:268-293 (2000). 
McCafferty et al., “Phage Antibodies: Filamentous Phage Display- 
ing Antibody Variable Domains,” Nature 348(6301):552-554 
(1990). 
McLaEerty et al., “M13 Bacteriophage Displaying Disulfide-Con- 
strained Microproteins,” Gene 128(1):29-36 (1993). 
Ostergaard et al., “Novel Avidin and Streptavidin Binding 
Sequences Found in Synthetic Peptide Libraries,” FEBS Letters 
362(3):306-308 (1995). 
Roberts and Szostak, “RNA-Peptide Fusions for the In Etro Selec- 
tion of Peptides and Proteins,”Proc. Natl. Acad. Sci. USA 94: 12297- 
12302 (1997). 
Roberts, R.W. “Totally In Etro Protein Selection Using mRNA- 
Protein Fusions and Ribosome Display,” Curr. Opin. Chem. Biol. 
3:268-273 (1999). 
Schmidt and Skerra, “The Random Peptide Library-Assisted Engi- 
neering of a C-Terminal Affinity Peptide, Useful for the Detection 
and Purification of a Functional lg Fv Fragment,” Protein Eng 
6(1):109-122 (1993). 
(Continued) 
Primary Examiner-Karen Cochrane Carlson 
Assistant Examiner-Agnes Rooke 
(74) Attorney, Agent, or Firm-Clark & Elbing LLP 
(57) ABSTRACT 
The invention provides peptides with high afinity for 
streptavidin. These peptides may be expressed as part of 
fusion proteins to facilitate the detection, quantitation, and 
purification of proteins of interest. 
25 Claims, 17 Drawing Sheets 
https://ntrs.nasa.gov/search.jsp?R=20080008632 2019-08-30T03:30:18+00:00Z
US 7,138,253 B2 
Page 2 
OTHER PUBLICATIONS Weber et al., “Crystal Stmcture and Ligand-Binding Studies of a 
Screened Peptide Complexed With Streptavidin,” Biochemistry 
Schmidt et al., “Molecular Interaction Between the Strep-Tag 31(39):9350-9354 (1992), 
Affinity Peptide and its Cognate Target, Streptavidin,” J.  Mol. Biol. 
255:753-766 (1996). Wilson et al., “The Use of mRNA Display to Select High-Affinity 
scott and smith, “Searching for peptide Ligands with an Epitope Protein-Binding Peptides,” PNAS 98(7):3750-3755 (2001). 
Librw,” Science 249(4967):386-390 (1990). Zang et al., “Tight-Binding Streptavidin Ligands From a Cyclic 
Szostak, J.W., “Evolution of Novel Proteins From Random-Se- Peptide Librw,” Bioorg. Med. Chem. Lett. 8(17):2327-2332 
quence Libraries” 2000 (Abstract). (1998). 
U.S. Patent Nov. 21,2006 Sheet 1 of 17 US 7,138,253 B2 
U.S. Patent Nov. 21,2006 Sheet 2 of 17 US 7,138,253 B2 
FIG.2 
U.S. Patent Nov. 21,2006 Sheet 3 of 17 US 7,138,253 B2 
U.S. Patent Nov. 21,2006 Sheet 4 of 17 US 7,138,253 B2 
U.S. Patent Nov. 21,2006 Sheet 5 of 17 
31- 
1 4 L  
l5 \ 
\ 
32’ 
17 
US 7,138,253 B2 
15 
FIG. 5A 
U.S. Patent Nov. 21,2006 Sheet 6 of 17 
31- 
12 -
32’ 
17 
US 7,138,253 B2 
FIG.58 
U.S. Patent Nov. 21,2006 Sheet 7 of 17 
22 
US 7,138,253 B2 
25 
FIG.6 
U.S. Patent Nov. 21,2006 Sheet 8 of 17 
17 
US 7,138,253 B2 
14 
L 
‘i 
19- 3 
25 
FIG. 7 
U.S. Patent Nov. 21,2006 Sheet 9 of 17 
44 
I 
I 
I 
I 
I 
I 
I 
I 
I 
36 I 
‘9 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
34 ,, 
w 
u 
t 
42 I 
* I  
I 
I 
I 
I 
I 
I 
35 I 
I I  
\ I  
Y 
I 
I 
I 
18 I 
‘ I  
I 
I 
I 
I 
I 
I 
I 
I 
I 
‘43 
\\ J 
FIG.8 
US 7,138,253 B2 
U 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
-I 
I 
I 
I 
I 
I 
I 
I 
I 
.So Patent Nov. 21,2006 Sheet 10 of 17 US 7,138,253 
67 
\r 
I 
I 
I 
I 
I 
I 
I 
I 
I 
65 I 
\I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
1 
I 
I 
I 
FIG.9 
52 
B2 
U.S. Patent Nov. 21,2006 Sheet 11 of 17 
b 
RU 
45 
40 
g 35 
z 
% 
El 
s 
3 
Z 
0 a 30 
CIL 
s 
25 
20 
15 
US 7,138,253 B2 
a 
I I I I I I I 
-400 -200 0 200 400 600 800 1000 
TIME (SECONDS) 
Fig. 10A 
U.S. Patent Nov. 21,2006 
RU 
400 
350 
300 
Y, 250 t 
Z 
3 
Sheet 12 of 17 US 7,138,253 B2 
I I 
I I I I I I 
-200 0 200 400 600 800 1000 1200 1400 
TIME (SECONDS) 
Fig. 106 
U.S. Patent Nov. 21,2006 Sheet 13 of 17 US 7,138,253 B2 
Fig. 11 
U.S. Patent Nov. 21,2006 Sheet 14 of 17 US 7,138,253 B2 
U.S. Patent Nov. 21,2006 Sheet 15 of 17 US 7,138,253 B2 
A A A A A  
s" 4 4 4 4  
U.S. Patent Nov. 21,2006 Sheet 16 of 17 US 7,138,253 B2 
A 
0 
Cr, 
A 
N 
N 
U.S. Patent Nov. 21,2006 Sheet 17 of 17 US 7,138,253 B2 
Fig. 15 
US 7,138,253 B2 
1 2 
STREPTAVIDIN-BINDING PEPTIDES AND 
USES THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
pM. The amino acid sequence of the peptide does not 
contain an HPQ, HPM, HPN, or HQP motif. Preferably, the 
dissociation constant is equal to or less than 5 pM, 1 pM, 100 
nM, 50 nM, 25 nM, 10 nM, or 5 nM. In one preferred 
5 embodiment, the dissociation constant is less than 10 pM, 5 
pM, 1 pM, 100 nM, 50 nM, or 25 nM; and greater than 0.01 
This application is a divisional of U.S. application Ser. nM, 0.1 nM, 1 nM, 5 nM, or 10 nM. In another preferred 
No. 101004,381, filed Oct. 31, 2001 now U.S. Pat. No. embodiment, the value of the dissociation constant is con- 
6,841,359, which claims benefit from U.S. Provisional tained in one of the following ranges: 5 pM to 1 pM, 1 pM 
Application No. 601244,541, filed Oct. 31, 2000, hereby i o  to 100 nM, 100 nM to 50 nM, 50 nM to 25 nM, 25 nM to 
incorporated by reference. 10 nM, 10 nM to 5 nM, 5 nM to 1 nM, or 5 nM to 0.1 nM, 
inclusive. 
In another related aspect, the invention provides a peptide 
which binds streptavidin with a dissociation constant less 
15 than 23 nM, 10 nM, or 5 nM. In one preferred embodiment, 
This invention was funded by grant number the peptide is disulfide bonded or cyclized. In another 
preferred embodiment, the dissociation constant is less than 
23 nM, 10 nM, or 5 nM; and greater than 0.01 nM, 0.1 nM, 
or 1 nM. In another preferred embodiment, the value of the 
20 dissociation constant is contained in one of the following 
ranges: 20 nM to 10 nM, 10 nM to 5 nM, 5 nM to 1 nM, or 
5 nM to 0.1 nM, inclusive. 
In other related aspects, the invention provides nucleic 
methods for purifying or detecting proteins of interest. acids encoding the peptides of the present invention, and 
three-dimensional structure of a protein often requires the In addition, standard gene fusion techniques may be used 
Purification of the Protein from a complex mixture of other to generate fusion nucleic acids that encode fusion proteins 
components, such as compounds Present in a cell lysate or which include a peptide of the present invention and a 
in vitro translation extract. With the number of known protein of interest, The fusion proteins may be purified, 
Proteins increasing dramatically as a result ofwhole genome 30 detected, or quantified based on the high affinity of the 
sequencing projects, it has become crucial to find alterna- peptides for streptavidin, 
tives to traditional, time-consuming monoclonal antibody Accordingly, in one such aspect, the invention provides a 
production for generating affinity reagents for the detection fusion protein including a protein of interest covalently 
and purification of proteins. In addition, purifying a novel linked to one ofthe following peptides: (a) a peptide which 
Protein using traditional column chromatography methods 35 binds streptavidin with a dissociation constant less than 10 
often requires much trial and error to develop a purification pM and which is not disulfide bonded or cyclized, (b) a 
Protocol that results in the recovery of the Protein in high peptide which binds streptavidin with a dissociation constant 
yield and purity. less than 10 pM and which does not contain an HPQ, HPM, 
Thus, purification methods are needed that may be gen- HPN, or HQP motif, or (c) a peptide which binds strepta- 
erally applied to proteins of interest, that utilize inexpensive 40 with a dissociation constant less than 23 nM. In 
reagents, and that result in highly purified protein without preferred embodiments, the peptide is attached to the amino- 
requiring multiple chromatography steps. terminus or the carboxy-terminus of the protein of interest, 
or the peptide is positioned between the amino and carboxy- 
termini of the protein of interest. Preferably, the peptide is 
45 linked to the protein of interest by a linker which includes a 
The purpose of the present invention is to provide protease-sensitive site. 
improved reagents for the purification, detection, or quan- In related aspects, the invention provides nucleic acids 
titation of proteins of interest. In particular, the high affinity, encoding the fusion proteins of the present invention, and 
streptavidin-binding peptides of the present invention may vectors that include these fusion nucleic acids. 
be used as affinity tags for the purification of fusion proteins 50 In addition, the invention provides a method of producing 
containing proteins of interest. a fusion protein of the present invention. This method 
Accordingly, in a first aspect, the invention provides a includes transfecting a vector having a nucleic acid sequence 
peptide which binds streptavidin with a dissociation constant encoding the fusion protein into a suitable host cell and 
less than 10 pM (that is, binds streptavidin more tightly than culturing the host cell under conditions appropriate for 
a KD of 10 pM) and which is not disulfide bonded or 55 expression of the fusion protein. 
cyclized. Preferably, the dissociation constant is equal to or The fusion proteins described herein may be used in 
less than 5 pM, 1 pM, 100 nM, 50 nM, 25 nM, 10 nM, or methods for purifying proteins of interest from samples. 
even 5 nM. In one preferred embodiment, the dissociation Such a method involves expressing the protein of interest as 
constant is less than 10 pM, 5 pM, 1 pM, 100 nM, 50 nM, a fusion protein covalently linked to one of the following 
or 25 nM; and greater than 0.01 nM, 0.1 nM, 1 nM, 5 nM, 60 peptides: (a) a peptide which binds streptavidin with a 
or 10 nM. In another preferred embodiment, the value of the dissociation constant less than 10 pM and which is not 
dissociation constant is contained in one of the following disulfide bonded or cyclized, (b) a peptide which binds 
ranges: 5 pM to 1 pM, 1 pM to 100 nM, 100 nM to 50 nM, streptavidin with a dissociation constant less than 10 pM and 
50 nM to 25 nM, 25 nM to 10 nM, 10 nM to 5 nM, 5 nM which does not contain an HPQ, HPM, HPN, or HQP motif, 
to 1 nM, or 5 nM to 0.1 nM, inclusive. 65 or (c) a peptide which binds streptavidin with a dissociation 
In a related aspect, the invention provides a peptide which constant less than 23 nM. A sample containing the fusion 
binds streptavidin with a dissociation constant less than 10 protein is contacted with streptavidin under conditions that 
STATEMENT AS TO FEDERALLY SPONSORED 
RESEARCH 
ROlGM53936 from the National Institutes of Health and 
grant number NCC-2-1069 from NASA. The government 
may have certain rights in the invention. 
BACKGROUND OF THE INVENTION 
In general, the invention features novel compounds and 
Determining the enzymatic activity, binding specificity, or 25 vectors that include such nucleic acids, 
SUMMARY OF THE INVENTION 
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3 
allow complex formation between the fusion protein and 
streptavidin. The complex is isolated, and the fusion protein 
is recovered from the complex, thereby purifying the protein 
of interest from the sample. In one preferred embodiment, 
the protein of interest is recovered from the fusion protein by 
cleaving the streptavidin-binding peptide from the fusion 
protein. 
In yet another aspect, the invention provides a method of 
detecting the presence of a fusion protein of the present 
invention in a sample. This method includes (a) contacting 
the sample with streptavidin or a streptavidin-containing 
compound under conditions that allow complex formation 
between the fusion protein and either streptavidin or the 
streptavidin-containing compound; (b) isolating the com- 
plex, and (c) detecting the presence of streptavidin or the 
streptavidin-containing compound in the complex or follow- 
ing recovery from the complex. The presence of streptavidin 
or the streptavidin-containing compound indicates the pres- 
ence of the fusion protein in the sample. Preferably, step (c) 
also involves measuring the amount of streptavidin or the 
streptavidin-containing compound in the complex or follow- 
ing recovery from the complex. The amount of fusion 
protein in the sample is correlated with, and may be calcu- 
lated from, the measured amount of streptavidin. For 
example, for a fusion protein containing a peptide that binds 
one molecule of streptavidin per molecule of peptide, the 
amount of fusion protein in the sample is predicted to be 
approximately the same as the amount of streptavidin mea- 
sured. In one preferred embodiment, the amount of strepta- 
vidin is determined using Western or ELISA analysis with an 
antibody that reacts with streptavidin or that reacts with a 
compound that is covalently linked to streptavidin. In 
another preferred embodiment, streptavidin is covalently 
linked to an enzyme, radiolabel, fluorescent label, or other 
detectable group, and the amount of streptavidin is deter- 
mined using standard techniques based on a characteristic of 
the detectable group such as its enzyme activity, radioactiv- 
ity, or fluorescence. 
In another aspect, the invention features a method of 
determining the affinity of a compound of interest for a 
target molecule. The method includes incubating a solution 
having a compound of interest with a detectable group and 
a free target molecule under conditions that allow complex 
formation between the compound of interest and the free 
target molecule. The solution is contacted with a target 
molecule immobilized on a solid support under conditions 
that allow complex formation between the compound of 
interest and the immobilized target molecule, and the com- 
pound of interest bound to the immobilized target molecule 
is then separated from the compound of interest not bound 
to the immobilized target molecule. To determine the affin- 
ity, either the amount of the compound of interest that is 
bound to the immobilized target or the amount of the 
compound of interest not bound to the target molecule is 
then measured. In yet another preferred embodiment, the 
steps of this method are repeated one or more times with a 
different concentration of free target molecule. In other 
preferred embodiments, both the amount of the compound 
of interest bound to the immobilized target molecule and the 
amount of the compound of interest not bound to the 
immobilized target molecule are measured. In another 
embodiment, only the amount of the compound of interest 
that is not bound to the immobilized target molecule is 
measured. In another embodiment, the target is immobilized 
on a solid support such as a microtiter plate, a bead, or the 
matrix of a spin-filter column. In another embodiment, the 
compound of interest that is bound to the immobilized target 
4 
molecule is separated from the coumpound of interest that is 
not bound to the immobilized target molecule by centrifu- 
gation, for example, by spin-filtration or ultracentrifugation. 
In still other preferred embodiments, the target is a small 
5 molecule such as streptavidin, a streptavidin fusion protein, 
streptavidin covalently bound to an enzyme (e.g. horseradish 
peroxidase or alkaline phosphatase), or a ligand. The com- 
pound of interest may be a peptide that binds streptavidin, or 
may be a fusion protein that includes a peptide that binds 
lo streptavidin and a protein of interest. In other embodiments, 
the compound of interest may be labeled with a detectable 
group, such as a radiolabel, a fluorescent molecule, or an 
enzyme. 
In preferred embodiments of various aspects of the inven- 
tion, the amino acid sequence of the peptide includes at least 
10,25, 50,75, or 100 consecutive amino acids or consists of 
between 5 and 150, 10 and 100, 20 and 75, or 30 and 50 
amino acids, inclusive, of any one of SEQ ID Nos. 1-29 or 
20 35. Preferably, the amino acid sequence of the peptides 
includes an LPQ, QPQ, EPQ, HPA, HPD, or HPL motif. In 
other preferred embodiments, the amino acid sequence 
includes any one of SEQ ID Nos. 1-29 or 35. In still other 
preferred embodiments, the peptide has an amino acid 
25 sequence that is at least 20, 30,40, 50, 60, 70, 80, 90, 95, or 
100% identical to any one of SEQ ID Nos. 1-29 or 35. 
It is also contemplated that the affinity of the peptides of 
the present invention for streptavidin may be increased by 
incorporating disulfide bonds into, or cyclizing, the peptides. 
30 By constraining the peptides, the amount of disorder inher- 
ent in the peptides (i.e., entropy) decreases, and thus binding 
of these peptides to streptavidin may require less energy. It 
is also contemplated that the three-dimensional structure of 
peptides of the invention bound to streptavidin may be 
35 experimentally determined or modeled based on the known 
crystal structure of streptavidin and used to determine pos- 
sible modifications to the peptides that may further improve 
their affinity for streptavidin. 
As used herein, by “nucleic acid” is meant a sequence of 
40 two or more covalently bonded naturally-occurring or modi- 
fied deoxyribonucleotides or ribonucleotides. 
By “peptide” is meant a sequence of two or more 
covalently bonded naturally-occurring or modified amino 
45 acids. The terms “peptide” and “protein” are used inter- 
changeably herein. 
By “covalently linked” is meant covalently bonded or 
connected through a series of covalent bonds. A group that 
is covalently linked to a protein may be attached to the 
50 amino-terminus, carboxy-terminus, between the amino- and 
carboxy-termini, or to a side chain of an amino acid in the 
protein. 
By “streptavidin” is meant any streptavidin molecule or 
fragment thereof or any protein that has an amino acid 
55 sequence that is at least 80, 90, 95, or 100% identical to a 
streptavidin molecule or fragment thereof (see, for example, 
Haeuptle et al. J. Biol. Chem. 258: 305, 1983). A preferred 
fragment of streptavidin is “core” streptavidin, which is a 
proteolytic cleavage product of streptavidin (Bayer et al. 
60 Biochem. J. 259,369-376, 1989). Preferably, a streptavidin 
molecule or fragment thereof is capable of binding biotin or 
any other streptavidin-binding molecule. Streptavidin or a 
streptavidin fragment may be modified chemically or 
through gene fusion technology or protein synthesis so that 
65 it is covalently linked to an enzyme, radiolabel, fluorescent 
label, or other detectable group. These detectable groups 
may be used to determine the presence or location of a 
15 
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streptavidin-bound fusion protein in a cell or sample or to may be universally applied to any protein. In addition, if 
quantify the amount of a streptavidin-bound fusion protein, desired, the streptavidin-binding peptide may be connected 
using standard methods. to the protein of interest through a protease cleavable linker, 
By a “streptavidin-containing compound” is meant any allowing removal of the peptide after purification of the 
compound that includes streptavidin covalently bound to 5 fusion protein. 
another molecule. These compounds may, for example, be Using the methods described herein, purification of a 
conjugated to streptavidin through gene fusion technology fusion protein based on its affinity for streptavidin has 
or Protein Synthesis and may, for example, be covalently allowed the isolation of the fusion protein in significantly 
linked to an enzyme, such as horseradish Peroxidase Or higher purity than that obtained using a hexahistidine affinity 
alkaline Phosphatase, a fluorescent group, a radiolabel, Or 10 tag or maltose-binding protein affinity tag. Moreover, 
any other detectable group. streptavidin is an inexpensive reagent that may be purchased 
unmodified or covalently labeled with a detectable group 
is not bound to a solid support. (such as FITC-streptavidin or alkaline phosphatase-conju- 
gated streptavidin) or with a chromatography matrix (such 
cyclized by the formation of a covalent bond between the 15 as streptavidin-agarose). The availability of these reagents 
N-terminal amino group of the peptide or the side-chain of simplifies methods for detecting and purifying the fusion 
a residue and the C-terminal carboxyl group or the side- proteins of the present invention, 
chain of a residue. For example, a peptide lactam may be In addition, the streptavidin binding peptide-tag are par- 
formed by the cyclization between the N-terminal amino ticularly useful when intermediate amounts of protein 
group or an amino group of an amino acid side-chain and the 20 (-16500 pg) need to be produced and purified in a high 
Or amide contain- throughput manner. For example, highly parallel purification 
ing side-chain. Other possible cyclizations include the for- protoco~s may be performed in 96-well plates using strepta- 
mation of a thioether by the reaction of a thiol group in a vidin-derivatized magnetic beads and streptavidin binding 
cysteine side-chain with the N-terminal amino group, C-ter- peptide-tagged proteins expressed in E, coli or in coupled in 
acid. A be formed between two fication, for example, for proteomics applications in which 
cysteine residues. As used herein, a “non-cyclized peptide” thousands of purified proteins need to be generated and 
is a linear peptide that does not have any of the above purified in parallel, 
Other features and advantages of the invention will be cyclizations. 
apparent from the following detailed description and from 
the claims. stant for binding streptavidin as measured using the elec- trophoretic mobility shift assay described herein. By “less 
than” a particular dissociation constant is meant capable of 
binding streptavidin more tightly than the strength of bind- 
By “purifying,, is meant separating a compound, for 
accompany it. Typically, a protein is substantially pure when 
BY “free target molecule” is meant a target molecule that 
BY ‘‘CYcliZe~’ is meant a on hear. A Peptide may be 
group Or a 
minal carboxyl group, or the side-chain of another amino 25 vitro transcription/translation reactions.  his facilitates puri- 
bond may 
By “dissociation constant” is meant the dissociation con- 30 
BRIEF DESCRIPTION OF THE DRAWINGS 
ing represented by a particular dissociation constant. 35 
FIG. 1A is a schematic illustration of an in vitro selection 
scheme. Members Of the DNA 
example, a protein, from other components that naturally process according to the invention, showing the Of 
the library and the 
it is at least 50%, by weight, free from proteins and nab-  
rally-occurring organic molecules with which it is naturally 40 promoter (T7), a tobacco mosaic 
library have, from the 5‘ to 3’ end, a T7 RNA polymerase 
enhancer 
associated. Preferably, the protein is at least 75%, more (TMV), a start codon (ATG), ” random acids, a 
preferably, at least 90%, and most preferably, at least 99%, hexahistidine tag (H6), and a 3’ ‘Onstant region (Const). 
by weight, pure. In other preferred embodiments, the protein FIG. 1B is a Picture of an SDS-PAGE gel of samples from 
is at least 2,5, 10,25, 50, or 100 times as pure as the starting the library at different stages of Preparation. The first lane 
material. Purity may be assayed by any appropriate method, 45 Shows the result of translating the mRNA display template 
such as po~yacry~amide g l e~ectrophoresis, column chro- with 35S-methionine. Most of the counts represent free 
matography, optical density, HPLC analysis, western analy- Peptide (free Pep), but a significant amount of mRNA- 
sis, or ELISA (see, for example, Ausubel et al., Current Peptide COvalent fusions are also Present (mRNA-PeP). 
protoco~s in ~ ~ l ~ ~ ~ l ~ ~  ~ i ~ l ~ ~ ,  john wiley & sons, N~~ There is also another band that is independent of added 
York, 2000). 50 template (NS, non-specific), and some counts remain in the 
B~ ‘Grecovered from the complex” is meant physically gel well. The band corresponding to the mRNA-peptide can 
separated from the complex of streptavidin and the fusion be shifted to a Position Slightly higher than that for the free 
protein. For example the streptavidin-bound fusion protein Peptide by the addition of RNase A. The remaining lanes 
may be incubated under conditions that reduce the of show the result of successive oligo-dT and Ni-NTA purifi- 
the fusion protein for streptavidin (i.e., at low or high salt 55 cations, and finally reverse transcription 
concentrations or at low or high pH values) or incubated in FIG. 2A is a bar graph showing the fraction of 35S counts 
the presence of molecules that compete with the fusion from the displayed peptides that bound to streptavidin and 
protein for binding streptavidin. Preferably, either the fusion eluted with biotin, at each round of selection. FIG. 2B is a 
protein or the streptavidin that has been released from the graph showing the elution profile for the peptide library 
complex is isolated using standard procedures, such as 60 generated from the output of the seventh round of selection 
column chromatography, polyacrylamide gel electrophore- in FIG. 2A. The first fraction represents the flow-through. 
sis, HPLC, or western analysis. Biotin was added at the point indicated. The plot compares 
The present invention provides a number of advantages the binding of the intact, reverse-transcribed, displayed 
related to the detection and purification of proteins of peptides (mRNA-pep), the same sample treated with RNase 
interest. For example, because the present methods do not 65 A, and the RNase-treated sample applied to a streptavidin 
require the generation of an antibody or other affinity reagent column pre-saturated with biotin (excess biotin was washed 
that is specific for each protein of interest, these methods away prior to exposing the library to the matrix). 
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FIG. 3 is a list of the sequences of 20 clones from the Ligation of pre-selected cassettes which have been cleaved 
seventh round of selection (SEQ ID Nos.: 1-20). The “#” with these enzymes yields the full-length DNA library. 
column indicates the number of times each sequence was FIG, 9A is the po~ynuc~eotide sequence of the vector 
sequences at the termini are underlined. The six C-terminal- 5 tein, a streptavidin-binding peptide (SEQ ID No,: 35, FIG, 
7A), and a hexahistidine tag. FIG. 9B is the amino acid most residues are not shown. 
sequence of the encoded fusion protein. The sequence of the 
amino acids of the SB19-C4 peptide is underlined, 
observed. The HPQ sequence is in bold type. Non-random encoding a fusion protein containing maltose-binding pro- 
4A is a picture Of a native gel showing an 
binding of four different DNA-tagged peptides to streptavi- 
din. The migration of each clone is shown in the absence (-) 
and presence (+) of 1 pM streptavidin. Some of the clones 
conformations, The show the position ofthe gel well, the dissociation of streptavidin from the fusion protein listed 
which often contains a fraction of the counts, FIG, 4~ is a in FIG. 9B immobilized on a biacore chip. For line “a,” the 
picture ofa  native gel showing the titration ofthe full-length 15 streptavidin concentration is 23 pM; for line “b,” the con- 
clone SB19 with streptavidin, The streptavidin concentra- centration is 11.5 pM, and for line “c,” the concentration is 
tion in each lane, from left to right, is: 3.8, 6.6, 10, 15, 23, 5.75 PM. This data was used to calculate an upper limit of 
35, and 61 n ~ ,  FIG, 4 c  is a curve fit ofthe data shown in 2xlu3/S  for the dissociation rate, KD FIG. 10B is a graph 
FIG, 4~ (the fraction of peptide bound could not be accu- showing the association and subsequent dissociation of 
rately determined for the point with the lowest concentration 20 streptavidin from the immobilized fusion protein. For lines 
of streptavidin), ~~~~~i~~ that the peptide is homogeneous “a” through “f,” the streptavidin concentrations are 1.6, 0.8, 
and 100% active, the data from this experiment give a KD of 0.4, 0.2, 0.1, and 0.05 PM, respectively. This data was used 
10 nM for the binding of peptide SB19 to streptavidin. to calculate an association rate, k,, of 5x104/Mls. 
FIG. 5 is a list of the sequences of truncation mutants of FIG. 11 is a map of the PTAG2K vector indicating the 
peptide 3319 (SEQ ID N ~ ~ , :  21-29), The full-length (FL), 25 order of the domains in the multiply-tagged fusion protein it 
C-terminal deleted (Cl-C4), N-terminal deleted (N-N3),  codes. 
and point mutated (Ml) peptide sequences are shown. The FIG. 12 is a graph showing a KD determination of the 
“% binding” refers to the performance of these peptides in streptavidin binding peptides-streptavidin interaction using 
the streptavidin column-binding assay. the Spin-filter Binding Inhibition Assay (SBIA). The labeled 
FIG. 6A is the nucleotide sequence of the plasmid used for 30 StrePtavidin binding PePtide-tagged Peptide was incubated 
expression of a fusion protein containing a streptavidin- with a range of streptavidin concentrations and the amount 
binding peptide (SEQ ID N ~ , :  37). FIG, 6~ is the amino acid not complexed was then determined after a short incubation 
sequence of the encoded protein (SEQ ID N ~ , :  38) which with immobilized streptavidin. This analysis gave a KD of 
contains, from the amino- to carboxy-terminus, maltose- 35 2.5 nM for the interaction of the streptavidin binding peptide 
binding protein, a streptavidin-binding peptide (SEQ ID sequence With StrePtaVidin. 
No.: 35, FIG. 7A), a hexahistidine tag, and another peptide FIG. 13 is a purity assay for a single-step purification of 
called 2rl8-19dN. FIG. 6C is the amino acid sequence of streptavidin binding peptide-tagged (multiply-tagged) pro- 
2rl8-19dN (SEQ ID No.: 39). tein from lysed cells. Purity is compared to samples pro- 
FIG, 7~ is the amino acid sequence of the streptavidin- 4o cessed upon the basis of the His-tag or the maltose-binding 
binding peptide (SEQ ID N ~ , :  35) used as an tag for protein sequences contained in the same protein. Lanes 1 
the purification ofthe fusion protein listed in FIG, 6 ~ .   hi^ and 2 show lysed E. coli prior to and after IPTG-induction, 
peptide contains the first 38 amino acids of the ~ ~ 1 9 - ~ 4  respectively. Lane 3 shows the soluble fraction of E. coli 
peptide (FIG, 5). FIG, 7~ is a picture of an SDS-PAGE gel lysate in streptavidin-binding buffer. Lanes 4 through 6 show 
showing the purity of the fusion protein after elution from 45 approximately equal amunts  of Purified Proteins from the 
the streptavidin column (lane 2) to the purity of elution fractions of the streptavidin binding peptide-tag 
the E, coli lysate that was applied to the column (lane 1). purification, the His-tag purification, and the maltose-bind- 
FIGS. 8 A 4 F  are schematic illustrations of the pre-selec- ing protein purification, 
tion method, FIG, 8~ is an illustration of an m~~~ display FIG. 14 illustrates a detection of a streptavidin binding 
template terminating in puromycin in which the tobacco 50 peptide-tagged protein with streptavidin-derivatized horse- 
mosaic virus translation enhancer sequence (TMV), the radish peroxidase. The left-hand panel shows the Coomassie 
initiating methionine codon (AUG), and the sections of the Brilliant Blue staining of an SDS-Tricine PAGE gel of the 
open reading frame encoding the two protein affinity tags Purified StrePtavidin binding PePtide-tagged (multiply- 
(FLAG and His,) are labeled. FIG. 8B is an illustration of an tagged) Protein and an E. Coli extract. These Same samples 
mRNA display template that is free of frameshifts and 55 were also run on a different Podion ofthe Same gel and then 
premature stop codons and thus encodes a full-length protein transferred to a nit~ocellulose ~ ~ ~ b r a n e .  Th  right-hand 
containing both tags, FIG, 8c illustrates an m~~~ panel shows the result of the probing of this membrane with 
display template that has initiated internally and displays the streptavidin-derivatized horseradish peroxidase. The only 
corresponding truncated protein lacking the N-terminal observed signal is for the streptavidin binding peptide- 
FLAG tag. FIG. 8D shows an mRNA display template that 60 tagged Protein, with no staining of other Proteins in the 
has a deletion in its open reading frame and thus displays the extract. 
corresponding frameshifted protein lacking the C-terminal FIG. 15 is a graph showing a KD determination of a 
Hiss tag. FIG. 8E illustrates the reverse transcription of the streptavidin binding peptide-streptavidin interaction. The y 
mRNA display template from FIG. 8B that was purified axis shows the fraction of surface-bound peptide that is 
based on the presence of both protein affinity tags in the 65 competed by the free streptavidin. This analysis gave a KD 
encoded protein. FIG. 8F shows the cleavage sites for Type of 2.4 nM for the interaction of the streptavidin binding 
11s restriction enzymes which are encoded in each cassette. peptide sequence with streptavidin. 
phoretic shift demonstrating the streptavidin-binding peptide which contains the first 38 
is a graph Of the Biacore (Surface 
show multiple bands, presumably representing different Resonance) response units over various lengths of time for 
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TABLE l-continued 
The present methods stem from the discovery of peptides % binding Standard 
that have unusually high affinities for streptavidin (KD of Peptide structure and eluting K, (nM) deviation (n) 
5 
One HPQ motif  less than 10 pM). These peptides were selected from a 
library of randomized, non-constrained peptides using the 
mRNA display method. The high affinity of the selected SB17 
SB18 58  
8.3 
peptides was particularly surprising, given the fact that SB19 85 10 1.8 (10) 
non-constrained linear peptide libraries generally do not i o  SB19 - c 4  88 4.9 0.88 (10) 
the protein normally functions in peptide recognition SB20 HPL 34  
yield high affinity ligands to proteins, except in cases where No HPQ motif  
(Clackton et al., Trends Biotech 12:173-184 (1994); Katz, 
Annu. Rev. Biophys. Biomol. Struct. 26:27-45, 1997). 
tides to streptavidin, truncation mutants for peptide SB19 be isolated using the mRNA display method or any other were constructed to determine which regions were necessary 
for high affinity streptavidin-binding (FIG. 5). Deletion of selection method, such as ribosome display (Roberts, Curr. 
up to 56 residues had no observable effect on the binding Opin. Chem. Biol. 3(3):268-73, 1999), or phage display 
20 strength. For example, peptide SB19-C4 retained only the (U.S. Pat. No. 5,821,047). 
The binding characteristics of exemplary dec ted  StrePta- first 38 residues from the selected construct (plus the C-ter- 
vidin-binding peptides are described in Table 1, and the minal sequence MMSGGCKLG, SEQ ID No.: 36) and had 
sequences of these peptides are listed in FIG. 3. The first a dissociation constant of 4.9 nM for streptavidin (Table 1). 
column of Table 1 lists the peptide name (SB1-SB20). For In contrast, N-terminal truncation mutations (NlLN3) 
comparison, a non-selected sequence with two HPQ motifs 25 resulted in a lower percentage of the encoded peptide 
spaced by 19 residues (called “non-selected’’) is listed in row specifically eluting from the streptavidin column (0.058 to 
one, SB19-C4 is a truncation mutant of peptide ~ ~ 1 9 ,  69% for the truncation mutants compared to 85% for full 
described below. The peptides are grouped according to the length SB19). These results sWgested that the determinants 
number of HPQ and similar tripeptide motifs they possess, for binding streptavidin were spread throughout the N-ter- 
The second column shows the number of tripeptide motifs in 30 minal 38 residues Of the SB1 
each peptide, and the number of amino acid residues sepa- High affinity streptavidin-binding peptides, such as those 
rating them. The third column represents the percentage of shown in have a number Of uses. For these 
column, This percentage ranged from 8,3% to as high as a protein of interest as a fusion protein joined to one or more 
35 of the streptavidin-binding peptides of the invention. In one 88% for the selected peptides, compared to only 0.16% for such purification method, a sample containing the fusion 
The fourth COlumn &ows the KD, when known, for the with no or weak affinity for streptavidin are washed away, 
interaction between streptavidin and the peptides, as mea- and the fusion protein is then selectively eluted from the 
s u r d  in the EMSA assay described herein. The standard 40 streptavidin matrix by addition of biotin, a biotin analog, 
deviation in the KD is shown in the fifth column, based on another streptavidin-binding peptide, or any compound that 
the number of independent measurements (n, shown in competes with the fusion protein for binding to the matrix. 
parentheses). The dissociation constant ranged from 110 nM Alternatively, the fusion protein may be eluted from the 
for peptide SB5 to 4.8 nM for peptides SB2. matrix by increasing or decreasing the pH of the buffer 
As described in detail below, this general protocol was 
used in a one-step purification of a fusion protein containing 
a streptavidin-binding peptide from an E. coli extract, result- 
ing in a high yield of very pure protein. This fusion protein 
50 contained the first 38 amino acids of the SB19-C4 peptide, 
which due to its small size was not expected to affect the 
three-dimensional structure or activity of the covalently- 
SB2 HPQ 1 9 H P Q  48  4.8 0.91 (8) linked protein of interest. Purification of fusion proteins 
SB3 H P Q 2 3 H P Q  20 containing other streptavidin-binding peptides of the present 
SB4 H P Q 4 3 H P Q  49 55 invention may be performed similarly. 
In addition, various modifications of the above purifica- SB5 H P Q 5 2 H P Q  72 110 
tion protocol would be apparent to one skilled in the art (see, 
Many other peptides with high for streptavidin may 15 To further characterize the binding Of the pep- 
peptide. 
peptide binding and specifically eluting from a streptavidin peptides may be used for protein purification by expressing 
the non-selected peptide with two HPQ motifs. protein is incubated with immobilized streptavidin, Proteins 
45 applied to the matrix. 
TABLE 1 
% binding 
Peptide Structure and eluting K, (nM) deviation (n) 
Non-selected HPQ 19 HPQ 0.16 
Two HPQ motifs 
5,7 (4) SB1 HPQ 1 9 H P Q  86 50 
22 (6) 
One HPQ and one similar tripeptide motif  
SB6 
SB7 
SB8 
SB9 
SBlO 
S B l l  
SB12 
SB13 
SB14 
SB15 
SB16 
HPL 4 HPQ 
HPD 7 HPQ 
HPQ 12 HPL 
HPQ 12 HP 
HPQ 21 Q P Q  
HPQ 28 HPA 
HPQ 30 EPQ 
HPQ 32 EPQ 
HPQ 43 HPL 
QPQ 50 HPQ 
HPQ 74 LPQ 
49 
28 
27 
64 
15 
68 
73 
64 
11 
44  s 
50 
for example, Ausubel eial., supra), and such modifications 
are included in the invention. In particular, use of the 
60 streptavidin-binding peptides as affinity tags is desirable for 
high throughput protein production and purification. For 
example, purification of fusion proteins in a multi-well 
format may be conducted using magnetic streptavidin beads 
that are washed and eluted robotically. The methods of the 
65 present invention may also be adapted to purify fusion 
proteins from in vitro translation mixtures or from other 
extracts, such as those from prokaryotic, yeast, insect, or 
12 16 (4) 
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mammalian cells, using standard techniques. If necessary, contrast, templates that contain frameshifts or premature 
avidin may be added to the extract to bind any free biotin in stop codons encode peptides without the C-terminal affinity 
the extract before contacting a sample from the extract with tag (FIG. 8D). Additionally, mRNA display templates that 
streptavidin. Allowing any free biotin to bind avidin may initiate internally produce peptides without the N-terminal 
prevent biotin from competing with the streptavidin-binding 5 affinity tag (FIG, 8 ~ ) .  The library of m~~~ displayed 
peptides for binding to streptavidin. peptides is enriched for peptides containing both affinity tags 
If desired, the presence of a fusion protein of the invention by purification ofthe m~~~ displayed peptides based on the 
with streptavidin.(i.e., unlabeled streptavidin or streptavidin supra), F~~ example, the m~~ displayed peptides may be 
that is labeled with a detectable group) under conditions that 10 applied to a matrix designed to bind peptides containing one 
allow streptavidin to bind the fusion protein. Preferably, the ofthe affinity tags, and the m~~~ display peptides without 
unbound streptavidin is separated from the streptavidin- the affinity tag are washed away, ne m~~~ display pep- 
bound fusion protein. Then, the streptavidin that is bound to tides containing the affinity tag are then eluted and applied 
the fusion protein is detected. Alternatively, the streptavidin to a second matrix designed to bind the other affinity tag, 
bound to the fusion protein is physically separated from the 15  them^^^ display peptides recovered from this purification 
fusion protein and then detected, using standard methods. step are enriched for members containing both affinity tags 
fusion protein or that has been separated from the fusion peptides are reversed transcribed to generate double- 
an antibody that reacts with streptavidin or that reacts with 20 restriction enzymes, preferably, this restriction digestion 
streptavidin is covalently linked to an enzyme, radiolabel, DNA cassettes. The cleaved DNA cassettes are then ligated 
fluorescent label, or other detectable group, the amount of to generate the full-length DNA templates, 
streptavidin may be determined using standard techniques The experiments described above were carried out as based on a characteristic of the detectable group such as its 25 follows. enzyme activity, radioactivity, or fluorescence (see, for 
Generation of a Streptavidin-Binding Peptide Library 
may be contacted with a streptavidin-binding compound that 
in a may be detected by incubating the fusion protein presence of these tags (see, for example, Ausubel et al., 
For to detect streptavidin that is bound to the and thus for full-length peptides. These mRNA displayed 
protein, Or may be performed using stranded DNA. The amplified DNA is then cleaved by 
a removes the sequences encoding the affinity tags from the that is linked to streptavidin. If 
example, Ausubel et al., supra). Alternatively, streptavidin 
is linked to an enzyme, fluorescent proteins of interest takes advantage of the translation-termi- 
label, Or Other group 30 nating antibiotic puromycin, which functions by entering the 
The mRNA display method for selecting peptides or 
group, and the 
A site of ribosomes and forming a covalent bond with the may be assayed as described herein. 
an improved method to generate nascent peptide. By covalently attaching puromycin to the 3' 
synthetic DNA libraries encoding full-length proteins, which end of an mRNA, a covalent link between a polypeptide and 
may be used in a variety of selection methods to isolate its encoding message can be achieved in situ during in vitro 
proteins with desired binding affinities or activities. The 35 translation (Roberts et al,, curr, Opin, Stmct, Bioi, 
generation of libraries of proteins containing a desired 9:521-529, 1999; Liu et al,, Methods Enzymol, 
number of amino acids is often limited by the number of 318:268-293, 2000), These mRNA-peptide fusions can then 
internal initiation events that result in truncated proteins and by purified and subjected to in vitro selection, yielding the 
the number of frameshifts that result in either premature stop isolation of novel peptide ligands, 
codons or the removal of desired stop codons. For example, 40 
we have 
during solid phase DNA synthesis, insefiions and deletions 
which frameshifts may occur due to imperfect cou- 
A DNA library encoding polypeptides Of lox amino acids 
was synthesized as described (tho et al., The library 
cassette encoded a random peptide with a pattern Of polar 
piing and Capping efficiencies, In addition, the random consisted of short cassettes concatamerized together. Each 
ing in premature truncation of the encoded protein, To 45 versus non-polar amino acid side chains compatible with 
selection using the mRNA display technology is performed lowed by a C-terminal invariant region containing a hexa- 
to enrich the library of DNA cassettes for sequences encod- 
ing two protein affinity tags. These DNA cassettes lack 50 The library had a Complexity of 2.4X1014 at the DNA 
frameshifts and premature stop codons. The selected DNA level. It was transcribed Using T7 RNA Polymerase (FIG. 
cassettes are then cleaved with enzymes and lA), after which a "linker" oligonucleotide was added to the 
ligated to generate the full-length DNA library (FIGS. 3' end using T4 DNA ligase as described (Liu et al., supra; 
8A-8F) (Cho et al., J. Mol. Biol. 297:309-319, 2000). Cho et al., supra). The linker consisted of a 21 nucleotide 
In one preferred embodiment of this method, mRNA 55 long dA stretch, followed by a Polyethylene glycol linker, 
display templates that contain a translation enhancer fol~owed by the sequence dA-dC-dC-PuromYcin (LiU et al., 
sequence operably-linked to an open reading frame and that Supra). 
terminate in puromycin are generated as described previ- This puromycin-terminated mRNA was translated in 
ously (Cho et al., supra). The open reading frame encodes vitro, using the Ambion (Austin, Tex.) in vitro translation kit 
two different protein affinity tags, such as a FLAG tag and 60 under standard conditions for capped mRNA. The 10 mL 
a hexahistidine tag. Preferably, one of the tags is located at reaction mixture was supplemented with 2 mCi 35S-me- 
the amino-terminus of the encoded peptide, and the other tag thionine and a total methionine concentration of 10 pM. The 
is located at the carboxy-terminus. The mRNA display reaction mixture also included 300 nM of the library of 
templates are in vitro translated to generate mRNA dis- puromycin-linked mRNAmolecules. After 1 hour at 30" C., 
played peptides (Cho et al., supra). mRNA displayed pep- 65 MgCl, and KCl were added to 20 and 710 mM, respectively, 
tides encoded by templates that do not contain frameshifts or and the reaction mixture was further incubated at room 
premature stop codons should contain both affinity tags. In temperature for five minutes to increase the yield of dis- 
regions in DNA templates may encode stop codons, result- 
address these problems, we have developed a method in 
which small DNA cassettes are synthesized, and an in vitro 
forming an amphipathic a-he1ix Or fl-strand (Cho et al., 
The random region was 88 amino acids long, fol- 
tag 
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played peptides. This in vitro translation produced 1 .2x1014 
polypeptides linked via the puromycin moiety to their 
encoding mRNAs. 
These mRNA displayed peptides were then purified on 
oligo-dT cellulose (which binds to the oligo-dA sequence in 
the linker) to remove polypeptides not fused to mRNA. For 
this purification procedure, the reaction mixture was diluted 
10-fold into oligo-dT-binding buffer (1M NaCl, 50 mM 
HEPES, 10 mM EDTA, 0.25% Triton X-100, and 5 mM 
2-mercaptoethanol at pH 7.9) and 80 mg oligo-dT cellulose 
(type 7, Amersham-Pharmacia, Piscataway, N.J.) and incu- 
bated with agitation at 4" C. for 30 minutes. The mixture was 
applied to a column (Poly-Prep chromatography column, 
Biorad, Hercules, Calif.), drained, washed with 10 mL 
oligo-dT-binding buffer, washed with 10 mL oligo-dT-wash 
buffer (300 mM NaCl, 20 mM HEPES, 1 mM EDTA, 0.25% 
Triton X-100, and 5 mM 2-mercaptoethanol at pH 7.9), and 
washed with 1 mL of 0 . 5 ~  oligo-dT-wash buffer. The 
mRNA-displayed peptides were eluted with 4.5 mL water 
plus 5 mM 2-mercaptoethanol into tubes containing Triton 
X-100 and bovine serum albumin (BSA, New England 
Biolabs, Beverly, Mass.) at final concentrations of 0.15% 
and 15 pg/mL, respectively. 
The mRNA-displayed peptides that eluted from the oligo- 
dT cellulose column were further purified on Ni-NTA aga- 
rose, which binds to the hexahistidine tags on the polypep- 
tides, to remove any mRNA not fused to polypeptides. The 
eluted fractions from the oligo-dT cellulose purification 
were exposed to 0.5 mL Ni-NTA-agarose (Qiagen, Valencia, 
Calif.) in Ni-binding buffer [6 M guanidinium chloride, 0.5 
M NaCl, 100 mM sodium phosphate, 10 mM Tris(hy- 
droxymethyl)aminomethane, 0.1% Triton X-100, 5 mM 
2-mercaptoethanol, 4 pg/mL tRNA (Boehringer-Mannheim, 
Indianapolis, Ind.), and 5 pg/mL BSA at pH 8.0)] and 
incubated for 30 minutes at room temperature. The matrix 
was then drained, washed with 12 column volumes Ni- 
binding buffer, and eluted with the same buffer plus 100 mM 
imidazole. Eluted fractions were combined and de-salted 
using two successive NAP columns (Amersham-Pharmacia, 
Piscataway, N.J.) equilibrated in 1 mM Tris(hydroxymethy1) 
aminomethane, 0.01% Triton X-100, 50 pM EDTA, 0.5 mM 
2-mercaptoethanol, 0.5 pg/mL tRNA (Boehringer-Man- 
nheim, Indianapolis, Ind.), and 50 pg/mL BSA at pH 7.6). 
The mRNA portion was then reverse transcribed using 
Superscript I1 (Gibco BRL, Rockville, Md.) according to the 
manufacturers instructions, except that the mRNA concen- 
tration was about 5 nM and the enzyme concentration was 
1 UIpL. To ensure a high yield in the reaction, a mixture of 
two primers were used: 1 pM of "splint" from the splinted 
ligation (Cho et al., supra), and 1 pM of the 3' PCR primer. 
After 30 minutes at 42" C., the temperature of the reaction 
mixture was raised to 50" for 2 minutes, and then cooled 
over 5 minutes to room temperature to allow gradual peptide 
folding. Finally, the contents were de-salted using NAP 
columns and subjected to scintillation counting. By com- 
paring the 35S counts of the purified, reverse transcribed 
mRNA-peptide fusions to the 35S-methionine stock and 
taking into consideration the total methionine concentration 
in the translation reaction (10 pM), the number of displayed 
peptides in this sample was determined to be 6 . 7 ~ 1 0 ~ ~ .  This 
number also represents the complexity of the library, since 
it contained virtually no redundancy (the complexity of 
puromycin-linker template used in the translation exceeds 
the number of recovered displayed peptides by a factor of 
about 35). 
14 
Samples from the synthesis and purification of the mRNA 
displayed peptides were run on an SDS-PAGE gel, as shown 
in FIG. 1B. 
Selection of Streptavidin-Binding Peptides 
For selection of peptides with high afinity for streptavi- 
din, the above mRNA displayed peptide library was incu- 
bated with immobilized streptavidin (Ultralink immobilized 
streptavidin plus, about 4 mg/mL; Pierce, Rockford, Ill.) in 
streptavidin-binding buffer under reducing conditions (40 
mM Tris(hydroxymethyl)aminomethane, 300 mM KCl, 2 
mM EDTA, 0.1% Triton X-100, 5 mM 2-mercaptoethanol, 
100 pg/mL BSA, and 1 pg/mL tRNA at pH 7.4). The amount 
of gel used was 0.5 mL in a total volume of 5.5 mL. After 
15 incubating for 20 minutes at room temperature, the contents 
were loaded onto a disposable chromatography column, 
drained, washed with 14 column volumes of streptavidin- 
binding buffer, and eluted with five successive aliquots, at 10 
minutes intervals, of streptavidin-binding buffer plus 2 mM 
2o D-biotin (Sigma, St. Louis, Mo.) (FIG. 1A). The fraction of 
the library that survived this purification was 0.08%. Elution 
fractions were combined, de-salted on NAP columns, and 
then PCR-amplified to regenerate the double-stranded DNA 
library using the described conditions and primers in a 8 mL 
This concluded the first round of selection, and the 
remaining six rounds followed the same protocol except that 
the translation was scaled down 10-fold, and the number of 
column volumes for washing the streptavidin column was 
3o increased (32 volumes for round 2; 40 volumes for rounds 
3, 4 and 6; and 25 volumes for rounds 5 and 7). The 
streptavidin-binding selection for rounds 5 and 7 was per- 
formed directly on the streptavidin-column eluate from the 
preceding selection rounds, without intervening amplifica- 
35 tion (the biotin was removed by three successive passages 
through NAP columns). PCR products amplified after the 
seventh selection round were cloned using the TOP0 TA 
cloning kit (Invitrogen, Carlsbad, Calif.), following the 
manufacture's protocol. The fraction of the library that 
4o bound and eluted from the streptavidin column increased in 
each round, reaching 61% at round seven (FIG. 2A). 
Characterization of the Selected Library 
The eluate from the seventh round of selection was 
amplified by PCR. The resulting PCR DNA was used to 
45 synthesize a library of displayed peptides to confirm that the 
displayed peptides, rather than the RNA or DNA portion of 
the library constructs, were responsible for the interaction 
with streptavidin. Treatment of the library with RNAse Adid 
not reduce the extent of bindingielution from the matrix 
50 (FIG. 2B). Also, biotin-saturated streptavidin showed no 
binding to the peptide library (FIG. 2B). These results 
demonstrated that the interaction of the selected peptides 
with the streptavidin matrix was specific for the unligated 
protein, rather than for any other component of the matrix. 
Sequence Analysis of Selected Peptides 
Thirty-three randomly chosen clones from the PCR DNA 
from round seven were chosen for sequencing. Twenty 
different sequences were observed (FIG. 3). Surprisingly, all 
60 20 sequences were frame-shifted from the intended frame 
(frame 1) to frame 3 by deletion of two nucleotides or 
addition of one nucleotide. The designed pattern of polar and 
non-polar residues was therefore discarded, leaving an 
unpatterned, essentially random sequence. Prior to the selec- 
65 tion, about half of the library members were in frame 1 
throughout their entire open reading frames (Cho et al., 
supra). Frame 3 appears to have been enriched over frame 1 
5 
25 reaction mixture (Cho et al., supra). 
55 
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due to the increased frequency of the sequence HPQ. Frame and washed with 80 column volumes of streptavidin-binding 
1 has a low incidence (1:45,000 library members) of the buffer, and then eluted with three consecutive aliquots (3 
sequence HPQ due to the designed polarinon-polar pattern. column volumes each) of streptavidin-binding buffer plus 2 
By contrast, frame 3 had a much higher expected incidence mM biotin over a 15 minute period. All fractions (flow- 
of the HPQ sequence (1:64), similar in frequency to that of 5 through, washes, elutions, and irreversibly bound counts) 
a library of the same length and with equal mixtures of all were analyzed by scintillation counting to determine the 
four nucleotides at each position (1:193). Also, frame 3 was fraction of DTP that bound streptavidin and eluted with 
rich in histidine, thus allowing retention on the Ni-NTA biotin (Table 1). The non-selected clone in which two HPQ 
column. The Ni-NTA purification protocol was intended to motifs (separated by 19 amino acids) were introduced 
but was not performed under sufficiently stringent condi- DEAHPOAGPVDQADARLVQQGA 
tions so as to eliminate peptides with small numbers of LOHHPOGDRMMSGGCKLGTGY (SEQ ID No. 34), in 
histidines. Frame 2 had a high incidence of stop codons. which the underlined portions are identical the HPQ regions 
Nineteen of the 20 clones had at least one HPQ motif, and of clone SB2. 
five clones contained two such motifs (Table 1). The clones 15 The results of this analysis are shown in Table 1. For 
were organized according to the number of times the HPQ comparison, two HPQ motifs, separated by 19 residues, 
and related tripeptide motifs occur (Table 1). The number of were introduced into a control, unselected member of the 
amino acids between the two motifs, when present, ranged library. The low percentage of this control peptide that 
from four to 74. specifically eluted from the streptavidin column (0.1 6%) 
20 indicated that the presence of two HPQ motifs was not 
Binding Affinities of Peptides sufficient for high affinity binding. In contrast, a greater 
TO rapidly assay each of the 20 selected Peptides to percentage of the selected peptides (8.3 to 88%) was 
determine their affinity for streptavidin, a new method for retained on the column during the washing step and then 
Preparing, tagging and Purifying the Peptides was employed. specifically eluted with biotin. 
For generation ofthe DNA-tagged Peptides, Plasmids con- 25 The dissociation constants of the selected peptides for 
taining single inserts were used as templates for PCR- streptavidin were measuring using an electrophoretic mobil- 
amplification using the same 5' PCR primer as described for ity shift assay (EMSA). In this assay, DTp's were incubated 
the library construction (tho et al., supra), and a new 3' with varying amounts of pure streptavidin (Pierce Immu- 
Primer (5'-ATAGCCGGTGCCAAGCTTGcAGccGccA- nopure Streptavidin, Rockford, Ill.) in streptavidin-binding 
GACCAGT-3'; SEQ ID No. 3% which altered the 3' RNA 30 buffer plus 5% glycerol to increase the density of the 
sequence to ACUGGUCUGGCGGCUGCAAGc~G- solution so that it could collect at the bottom of the gel well. 
CKXXGGCUAU (SEQ ID No. 31). This sequence was After incubating at room temperature for 20 minutes, the 
designed to anneal to the Photo-crosslifing linker, which reactions mixtures were moved into the cold room, where 
has the sequence 5'-psoralen- they remained for 10 minutes before being carefully loaded 
TAGCCGGTG-A17-CC-PuromYcin-3', in which the under- 35 onto a 10% polyacry1amide:bisacrylamide (37.5: 1, National 
lined bases are 3'-methoxy nucleotides and the remaining Diagnostics, Atlanta, Ga,) gel (thickness 0.7 111111, height 16 
bases are deoxynucleotides (the oligonucleotide was syn- cm, width 18 cm) containing 2 x  TBE, 0.1% Triton x-100 
thesized using reagents from Glen Research, Sterling, Va.). and 5% glycerol, The gel, which had been pre-run for 30 
This new Primer changed the constant C-terminal Peptide minutes at 13 watts, and the running buffer were pre-cooled 
sequence from ~%3GCHHHHHHSSA (SEQ ID No. 32) to 40 to 4" C. Then, the gel was run in the cold room at 13 watts, 
~SGGCKLGTGY (SEQ ID No. 331, of which the last three which increased the temperature of the gel to about 20" C. 
amino acids may not be translated because they are annealed The gel was run for 45 to 120 minutes, depending on the 
to the linker. Each DNA template was transcribed and gel mobility of the particular DTP. Then, the gel was fixed in 
Purified as described (Cho et al., Supra), and then incubated 10% acetic acid and 10% methanol for 15 minutes, trans- 
with the psoralen linker under the following conditions: 2 45 ferred to electrophoresis paper (Ahlstrom, Mt. Holly 
PM mRNA, 4 PM linker, 50 mM Tris(hYdOxYmethY1) Springs, Pa.), dried, and analyzed using a Phosphorlmager 
aminomethane, 200 mM KCl, and 10 mM spermidine at pH (Molecular Dynamics, Sunnyvale, Calif,), 
7.4 and 70" c .  for 2 minutes, and then cooled to 4" c .  over The short DNA oligonucleotide tag on the DTP's allowed 
5 minutes. Samples were then placed in the cold room in a them to migrate in a native gel, and the addition of unlabeled 
96 well Plate (50 &/well), one inch above which was 50 ligand (Le., streptavidin) caused a mobility shift for several 
suspended a W lamp (366 m, Ultraviolet Products, Inc., of the clones. The concentration of DTPs was less than 1 nM 
Sari Gabriel, Calif., model number WL-21)  for 15 minutes. in each titration, and thus the dissociation constant (K,) can 
Then, the reactions mixtures were de-salted using a (3-50 be approximated by the concentration of streptavidin that 
SePhadex spin Column (Boefinger M a d e i m ,  IndianaPo- results in half of the DTP being mobility-shifted. To deter- 
lis, Ind.1. The translatioddisplay reactions and OligO-dT- 55 mine the K, several different measurements were taken in 
purification were carried out as above. Finally, RNaseA (200 the range of 25-75% of DTP bound (values outside of this 
@mL, 10 minutes, room temperature) was added to range were unreliable due to background and close proxim- 
degrade the mRNA, leaving Peptides fused to a Short DNA ity of the bound and unbound bands in the gel). The K, was 
oligon~cleotide. Complete degradation was confirmed by determined using the equation K,=[ streptavidin] *R, where 
SDS-PAGE analysis. 60 R is the ratio of unbound to bound DTP (ratio of unshifted 
The resulting purified DNA-tagged peptides (DTP) were to shifted band). Independent measurements on gels pre- 
analyzed in a streptavidin column-binding assay, in which pared at different times were used for each clone (the 
-500 pM 35S-labeled DTP were mixed with 50 pL of the number of different measurements, n, is shown in Table 1). 
streptavidin matrix in streptavidin-binding buffer, in a total Streptavidin concentrations were measured by W,,,, using 
volume of 300 pL, and incubated for 10 minutes at room 65 the molar extinction coefficient of 57,000 per monomer. 
temperature with agitation. Then, the contents were loaded Examples of these mobility shifts in the presence of 
onto a chromatography column. The column was drained streptavidin are shown in FIG. 4A. Some clones showed 
eliminate library mRNA molecules not displaying peptide, i o  encoded the sequence M 
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either no shift or poorly defined bands, suggesting that the 
lifetime of these complexes was too short for detection using 
this method. We chose five of the most well behaved clones 
and quantitatively examined their mobility shifts in response 
to a range of streptavidin concentrations. An example of a 
streptavidin titration experiment for peptide SB19 is shown 
in FIG. 4B, and the data is graphed in FIG. 4C. The 
dissociation constants for the clones ranged from 110 nM to 
less than 5 nM (Table 1). These surprisingly high affinities 
were comparable to those for monoclonal antibody-antigen 
interactions, demonstrating that even random, non-con- 
strained peptide libraries can be a source of avid ligands to 
proteins that do not normally function in peptide binding. 
Dissection of Clone SB19 
Clone SB19 possessed only one HPQ motif, bound to 
85% in the column binding assay, and had a KD for strepta- 
vidin of 10 nM (Table 1). A series of C-terminal truncation 
constructs (ClLC4) were constructed and assayed in the 
streptavidin column-binding assay (FIG. 5). C-terminal 
truncation analysis of clone SB19 was performed using 
standard methods by amplifying the clone with the original 
5' primer and a series of 3' primers that truncated the 
sequence at various positions and also replaced two codons 
(encoding Asp and Trp) in the C-terminal constant region 
with methionine codons to increase the 35S-incorporation. 
Analogous primers were used for the N-terminal truncation 
analysis, except that no change was made in the N-terminal 
constant sequence. 
Deletion of up to 56 residues had no observable effect on 
the binding strength. Peptide SB19-C4 retained only the first 
38 residues from the selected construct (plus the C-terminal 
MMSGGCKLG sequence, SEQ ID No. 36). Mutating the 
HPQ motif to HGA reduced the activity by three orders of 
magnitude (compare construct C4 to Ml). Results from the 
N-terminal truncation constructs (NlLN3) suggested that 
binding determinants were spread throughout the N-terminal 
38 residues of peptide SB19. Of the peptides tested, SB19- 
C4 was therefore the minimal peptide retaining full activity 
in this assay. EMSA analysis of peptide SB19-C4 confirmed 
high affinity streptavidin-binding, but a fraction (13%) of the 
peptide was inactive even at streptavidin concentrations > 1 
pM. The majority (87%), however, had an apparent KD of 
4.9 nM after correction for the amount of inactive peptide. 
Purification of Fusion Protein Containing Streptavidin- 
Binding Peptide 
A fusion protein containing the first 38 amino acids of the 
SB19-C4 streptavidin-binding peptide (FIG. 7A) was 
expressed in E. coli and then purified from the cell lysate. 
For the expression of the fusion protein, BL21 (DE3) cells 
were transformed with a plasmid containing a Maltose 
Binding Protein-Streptavidin-binding Peptide-His,-Pro- 
tein of Interest insert (FIG. 11) which encodes a fusion 
protein containing, from the amino- to carboxy-terminus, 
maltose-binding protein, the first 38 residues of the SB19- 
C4 sequence, a hexahistidine tag, and another peptide called 
2rl8-19dN (FIGS. 6A-6C). This insert was constructed 
using standard molecular biology techniques (see, for 
example, Ausubel et al., supra). Each of these domains of the 
fusion protein is separated by a few amino acids to allow 
proper folding of the domains. 
A kanamycin-resistant colony was selected and grown 
overnight in 10 ml LB media with 50 mglliter kanamycin at 
37" C. This starter culture was diluted 100-fold into 1000 ml 
LB with 50 mgiliter kanamycin, and the culture was grown 
at 37" C. to OD,,, of 1.6-1.8 at 37" C. Expression of the 
fusion protein was induced by addition of 1 mM IPTG, and 
18 
the culture was grown for another two hours. The cells were 
pelleted by centrifugation at 300&5000xg for 20 minutes. 
The pelleted cells were resuspended in 5% of the original 
volume of a buffer appropriate for the subsequent affinity 
5 purification method. For purification on an amylose column 
the cells were resuspended in 1 mM EDTA and MBP buffer 
(10 mM HEPES.HC1, 10 mM HEPES.Na', 200 mM KCl, 
0.25% wiw Triton X-100, and 10 mM BME at pH 7.4) and 
frozen slowly at -20" C. overnight. The sample was thawed 
i o  in the morning and sonicated on ice. The cell lysate was 
obtained by collection of the supernatant after centrifugation 
at 14,OOOxg for 20 minutes at 4" C. 
To purify the fusion protein, the cell lysate was applied to 
a column containing immobilized streptavidin, with a capac- 
15 ity of about 1 mgiml, that had been washed with eight 
column volumes of MBP buffer. Then, the column was 
washed with 12 column volumes of MBP buffer. The fusion 
protein was eluted with MBP buffer containing 2 mM biotin. 
Samples of the cell lysate and eluted protein were analyzed 
20 by SDS-PAGE on an 8% gel (FIG. 7B). The lane containing 
the purified protein had a band of the expected size. No other 
bands were observed, except for a faint band of slightly 
higher mobility (FIG. 7B). This band was probably a deg- 
radation product of the fusion protein that was missing a few 
25 amino acids from either the amino- or carboxy-terminus but 
retained the streptavidin-binding peptide and thus retained 
the ability to bind the streptavidin column. Thirty percent of 
the fusion protein loaded onto a column containing immo- 
bilized streptavidin was recovered after washing the column 
30 with 12 column volumes of buffer. Thus, the high affinity of 
the fusion protein for streptavidin allowed extensive wash- 
ing of the column to remove contaminating proteins, while 
retaining a significant amount of the desired fusion protein. 
More stringent conditions eliminated the contaminating 
35 protein of higher molecular weight. The soluble fraction of 
lysed induced cells was prepared in Streptavidin-binding 
buffer (SBB: 300 mM KCl, 40 mM Tris(hydroxymethy1) 
amino methane, 5 mM 2-mercaptoethanol, 2 mM EDTA, 
0.1% Triton-X 100, pH 7.4) as described above. This sample 
40 (e.g., 79 mg net weight cells in 1 ml SBB) was applied 
directly to the immobilized streptavidin matrix (e.g., column 
volume 100 pl; Ultralink Immobilized Streptavidin Plus, 
Pierce, Rockford Ill.) and then incubated at 4" C. for 30 
minutes. The matrix was then washed with 40 column 
45 volumes of SBB and then eluted with 3 successive 2 column 
volume aliquots of SBB containing 2 mM biotin for 10 
minutes each. Samples of each of the lysed uninduced and 
lysed induced cells, the soluble fraction, and the elution 
fraction were then analyzed on an 8% SDS-Tricine PAGE 
50 gel, and then stained with Coomassie Brilliant Blue. In a 
typical experiment, 1 ml of the soluble fraction of lysed 
induced cells was loaded onto 0.1 ml of the affinity matrix. 
Purification using the His-tag was also carried out in an 
analogous manner to the streptavidin binding peptide-tag 
55 procedure with the same amounts of cells and in the same 
volumes. The soluble fraction was prepared in His-tag 
binding buffer (300 mM NaCl, 50 mM sodium phosphate, 
0.25% Triton X-100, 10 mM imidazole, pH 8.0). The sample 
was applied directly to the Ni-column (Ni-NTA, Qiagen, 
60 Valencia Calif.) and then incubated at 4" C. for 30 minutes. 
The matrix was then washed with 40 column volumes of the 
same buffer containing 20 mM imidazole and then eluted 
with 3 successive 2 column volume aliquots of the same 
buffer containing 250 mM imidazole for 10 minutes each. 
65 Samples were analyzed as described above. 
Purification using the maltose-binding protein sequence 
was carried out in an analogous manner to the streptavidin 
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binding peptide-tag procedure with the same amounts of 
cells and in the same volumes. The soluble fraction was 
prepared in maltose-binding protein binding buffer (200 mM 
KCl, 20 mM HEPES, 10 mM 2-mercaptoethanol, 0.25% 
Triton X-100, pH 7.4). The sample was applied directly to 
the amylose column (New England Biolabs, Beverly Mass.) 
and then incubated at 4" C. for 30 minutes. The matrix was 
then washed with 40 column volumes of the same buffer and 
then eluted with 3 successive 2 column volume aliquots of 
the same buffer containing 10 mM maltose for 10 minutes 
each. 
For detection, ten picomoles of the loaded and eluted 
samples from the immobilized streptavidin column, the 
Ni-column, and the amylose column was loaded onto a 12% 
SDS-Tricine PAGE gel. In the adjacent lane, a whole bac- 
terial extract from BL21 (DE3) cells was loaded. The whole 
cell extract was prepared by growing the cells to saturation 
in LB, removing the media by centrifugation, and re- 
suspending them in 10% of the original culture volume with 
the SDS-PAGE protein-loading buffer. Six microliters of this 
extract was run on the gel. These two samples and a 
molecular weight marker were run side by side on the gel in 
duplicate. After running the gel, it was stained with Coo- 
massie Brilliant Blue 
This gel is shown in FIG. 13. A band of the correct size 
was purified using each of the three columns. Purification on 
immobilized streptavidin gave the highest purity sample. No 
other bands were visible by Coomassie Brilliant Blue- 
stained SDS-Tricine PAGE gel analysis. At least one impu- 
rity was detected in the Ni-NTA-purified sample, and several 
contaminants were apparent in the amylose-purified sample. 
These results suggest that the streptavidin binding peptide- 
tag provides superior purity after a single purification step 
from lysed induced cells. 
Detection of Fusion Proteins Containing Streptavidin Bind- 
ing Peptides Using Streptavidin-Derived Reagents 
Recombinant proteins containing streptavidin affinity tags 
may also be detected using reagents that bind to these 
affinity tags. A wide range of streptavidin-derivatized 
reagents is commercially available, and as a consequence the 
streptavidin binding peptide-tag provides a versatile detec- 
tion tool. To demonstrate the utility of this interaction, an 
experiment was performed in which a recombinant protein 
was probed with streptavidin-derivatized horseradish per- 
oxidase. 
In this experiment the multiply-tagged protein was puri- 
fied on the streptavidin column. The purified protein and an 
E. coli cell lysate were electrophoresed in adjacent lanes of 
a SDS-Tricine PAGE gel as described above. The protein on 
the gel was transferred to nitrocellulose (Trans-blot transfer 
medium, 0.2 pn, Biorad catalog number 162-0112) at 10 V 
for 30 minutes using the manufacturer's instructions (Trans- 
blot semi-dry transfer cell, Biorad catalog number 170- 
3940). Efficient protein transfer was confirmed by the pres- 
ence of the pre-stained molecular weight markers on the 
nitrocellulose. 
After transfer, the nitrocellulose was incubated in TBS (25 
mM TrisHC1, 138 mM NaCl, 2.68 mM KCl, pH 7.4) plus 
0.05% Polyoxyethylene-sorbitan monolaurate (Tween-20) 
and 3% BSA for 1 hour at room temperature. The blot was 
then briefly rinsed with the same buffer without BSA, and 
then a streptavidin-derivatized horseradish peroxidase con- 
jugate (Amersham-Pharmacia, product number RPN123 1) 
was added at a 1,000-fold dilution in TBS/O.O5% Tween- 
2013% BSA, and allowed to incubate for 1 hour at room 
temperature. The blot was then washed 3 times with TBSi 
20 
0.05% Tween-20, and then one time with TBS. The HRP 
substrate (3,3',5,5'-tetramethylbenzidene, Promega catalog 
number W4121) was then added according to the manufac- 
turers instructions, and the blot was developed for approxi- 
These results are shown in FIG. 14. The streptavidin 
binding peptide-tagged protein is readily observed, and no 
proteins from the E. coli lysate are labeled, thus indicating 
the specificity of this interaction. Streptavidin-derivatized 
10 horseradish peroxidase and other streptavidin-derivatized 
reagents therefore provide many alternative methods of 
detecting streptavidin binding peptide-tagged proteins on 
membranes, plates, tissue sections, et cetera. 
5 mately 1 minute. 
15 Yield of Fusion Proteins Containing Streptavidin-Binding 
Peptides 
When scaling up protein expression to one milligram and 
above, the capacity and expense of the affinity matrix often 
begins to become important. To measure the capacity of the 
20 three matrices described above for their respective tag 
sequences, each matrix was overloaded with the multiply- 
tagged protein. Cells over-expressing this protein were split 
into three aliquots and re-suspended in different buffers 
according to the matrix that was to be used. The sample 
25 applied to immobilized streptavidin was extracted into 
streptavidin-binding buffer, and the samples for the other 
two purifications were extracted into the buffers recom- 
mended by the manufacturers of the two matrices, as 
described above. 
The amount of protein in the flow-throughs, washes, and 
elution fractions was measured using the Bradford assay. We 
confirmed that each column was overloaded by observing 
the multiply-tagged protein in the flow-through fractions 
from each column. Purification using Ni-NTA agarose (His- 
35 tagiimidazole) yielded 12 mg of protein per ml of matrix. 
The amylose column yielded 4.4 mg of protein per ml of 
matrix. The immobilized streptavidin column yielded 0.5 
mg of protein per ml of matrix (0.53 mgiml with a standard 
deviation of 0.07 mgiml, ~ 4 ) .  The overall capacity of 
40 immobilized streptavidin for the streptavidin binding pep- 
tide-tag was therefore lower than that of the Ni-NTA agarose 
or amylose matrices for their respective tags, but signifi- 
cantly greater than that of immobilized antibody matrices for 
purifying proteins upon the basis of epitope tags. 
Biacore Analysis of the Affinity of a Fusion Protein for 
Streptavidin 
The SB19-C4 streptavidin-binding fusion protein was 
expressed and purified from E. coli. This fusion protein 
50 contained, from the amino- to carboxy-terminus, maltose- 
binding protein, the first 38 amino acids of the SB19-C4 
sequence, and a hexahistidine tag (FIG. 9B, SEQ ID No. 41). 
The plasmid (FIG. 9A, SEQ ID No. 40) encoding this fusion 
protein was constructed using standard molecular biology 
55 techniques and used to express the fusion protein in E. coli, 
as described above. This fusion protein was purified from 
the E. coli extract using amylose resin to bind the maltose- 
binding protein portion of the fusion protein and then 
Ni-NTA resin to bind the hexahistidine tag. 
To measure the affinity of the fusion protein for strepta- 
vidin, the fusion protein was immobilized on a biacore chip 
through the crosslinking of free amino groups in the fusion 
protein to the biacore chip. Buffer containing streptavidin 
was washed over the chip, allowing streptavidin to bind the 
65 immobilized fusion protein (FIG. 10B). This resulted in an 
increase in the biacore response units which are proportional 
to the amount of streptavidin adhering to the biacore chip. 
30 
45 
60 
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Then buffer without streptavidin was washed over the chip, By plotting the immobilized target-binding inhibition 
and the biacore response units decreased as streptavidin against the concentration of the free target, the K, can easily 
dissociated from the immobilized fusion protein (FIGS. 10A be derived. 
and 10B). TO measure the association rate for the binding of Because this titration is based on the interaction of the 
streptavidin to the fusion protein, streptavidin concentra- 5 Protein With the free (not immobilized) target, it may be 
tions of 1.6, 0.8, 0.4, 0.2, 0.1, or 0.05 p ~ ,  (lines -a” to y’ more accurate than methods that quantify peptide binding to 
in FIG,  OB, respectively) were washed over the biacore immobilized targets. However, SBIA may underestimate the 
chip, The buffer also contained 40 mM ~ r ~ s ( h y ~ o x y m e t h y ~ )  affinity if there is significant dissociation of the complex 
aminomethane, 3oo mM KCl, mM EDTA, o,l% wiv during the brief incubation with immobilized target. The K, 
Triton x-loo, and mM 2-mercaptoethanol at pH 7,4, This i o  corresponds to the concentration of free target that half- 
inhibits the binding to the immobilized target. As long as the data was used to calculate an association rate, k,, of 5x104/ concentration of the labeled binder is significantly lower 
M/s’ as described (BIACoRE Instrument than the K, the concentration of free target may be approxi- 
Handbook, version AA, Biacore AB, Uppsala Sweden, mated as the total concentration of added target. This method 
or 5.75 pM streptavidin in the buffer described above was for protein-protein, protein-peptide, and protein-small mol- 
administered, and then buffer without streptavidin was ecule comp~exes, 
washed Over the chip (FIG. 10A). This data was used to To measure the K, of the SB19-C4 peptide, this peptide 
calculate an upper limit of 2X10-3/S for the dissociation rate, was fused to a FLAG-tag (streptavidin binding peptide- 
KD (BIACORE X Instrument Handbook, supra). Based on 20 FLAG) (Wilson et al. P ~ o c .  Natl. Acad. Sci. USA 
these calculated association and dissociation rates, the dis- 98:3750-3755, 2001). Streptavidin binding peptide-FLAG 
sociation constant, K, for the binding of streptavidin by this was then translated in the presence of 35S-labeled methion- 
fusion protein was less than 40 nM. This result confirms the ine by in vitro translation in reticulocyte lysate according to 
high affinity binding of the SB19-C4 peptide for streptavidin the manufacturer’s instructions (Red Nova, Novagen, Madi- 
that was observed in the streptavidin column-binding assay 25 son, WiS.1 using a template concentration of400 nM, 1 mM 
and the EMSA assay (Table 1). Additionally, this result extra MgC1, and 100 mM extra KC1. This mixture was then 
demonstrates that this peptide maintains its high affinity for Purified successively upon the basis of the FLAG-tag and 
streptavidin when expressed as part of a fusion protein. then the His-tag (using the manufacturer’s instructions; 
denaturing conditions were used for the Ni-NTA purifica- 
Spin-Filter Binding Inhibition Assay Analysis of the Affinity 30 tion). The resultant purified peptide was then dialyzed into 
of a Fusion Protein for Streptavidin streptavidin-binding buffer (SBB: 300 mM KCl, 40 mM 
hanol, 2 mM EDTA, 0.1% Triton-X 100, pH 7.4). The second and more general method, termed a Spin-filter Bind- 
ing Inhibition Assay (SBIA), was also utilized, This method peptide was then diluted into the same buffer and mixed with 
35 a range of different streptavidin concentrations to give a set is especially appropriate for cases in which numerous pro- of 50 pl samples in which the SB19-FLAG peptide was at 
200 pM and the streptavidin concentration ranged from 30 teins or peptides are derived from in vitro selection tech- 
997). To the dissociation rate, a pulse Of 23, .5, 15 may be generally useful for the determination of K, values 
To measure the K, of the peptide described above, a Tris(hydroxymethyl) amino methane, mM 2-mercaptoet- 
niques using targets such as phage pM to 1 pM, Each of these samples was then incubated for 
(Smith, G. p. et al. Chem. Rev. 971391410> 19971, mRNA 2 hours at 00 C, and then subsequently incubated for 1 
(Roberts et al. proc. Natz. Acad. sei. USA 40 minute with 10 p1 samples ofthe washed and dried immo- 
94: 12297-12302, 1997; LiU et al. Methods Enqmol. 31 8: bilized streptavidin matrix (Ultralink Immobilized Strepta- 
268-293, 2000; Keefe et al. Current Protocols in Molecular plus, pierce, Rockford 111.). The flow-throughs were 
Biology 2001; et al. Nature 410:715-718, 2001) Or then immediately collected by centrifugation in a 0.2 pm 
~ibosome display (JermutuS et al. cum OPin. BioteChnol. DuraporeB spin-filter (Millipore, Bedford Mass.), and these 
91391-410, 1998). The Principal benefit of this method is 45 were counted in a scintillation counter. These data were 
that it allows the affinities and specificities of interacting iteratively fitted to the following equation y+,+c(Kd(K,+ 
proteins to be assayed before investing the time required to x)) in which was the number of radioactive decomposi- 
over-express and purify them in the quantities required for tions detected per minute in each flow-through, K, is the 
conventional affinity determinations. dissociation constant of the complex, x was the concentra- 
In general, SBIA utilizes low concentrations (CK,) of 50 tion of free streptavidin, b was the number of counts per 
S-labeled protein generated in a cell-free translation sys- minute not competent to bind the matrix under the assay 
tem. The labeled protein is exposed to the bead-immobilized conditions, and c was the number of counts per minute 
target (in this case immobilized streptavidin), and then the competent to bind the matrix under the assay conditions. K, 
flow-through is collected by centrifugation in a 0.2 pm b, and c were iteratively determined using the program 
DuraporeB spin-filter. The fraction of counts that pass 55 Deltagraph 4.0 (SPSS, Chicago Ill.). 
through the filter (and therefore did not bind to the column) In this experiment, the binding of labeled streptavidin 
35 
indicates the fraction of labeled peptide that did not bind to 
the matrix. To determine the affinity of the interaction, the 
labeled protein is first exposed to a range of concentrations 
of non-immobilized target. After this mixture has reached 60 
equilibrium, it is briefly (1 minute) exposed to the bead- 
immobilized target, and then spin-filtered as above. The 
initial incubation with the soluble target will compete with 
the binding of the radio-labeled protein to the immobilized 
target. The amount of inhibition is directly related to the 65 
fraction of labeled protein that was bound to the free target 
binding peptide-tagged peptide was inhibited by pre-incu- 
bation with free streptavidin (FIG. 12). In this experiment 
48% of the counts bound to immobilized streptavidin in the 
1 minute slurry incubation in the absence of free streptavidin 
competitor, and this binding was completely inhibited by 
high concentrations (>lo0 nM) of streptavidin. Analysis of 
the binding curve gave a K, of 2.5 nM, which compared 
very favorably with the K, determined by other methods. 
For example, the same peptide was purified on a FLAG- 
affinity matrix, then bound to streptavidin immobilized on a 
before this mixture was exposed to the immobilized target. microtiter plate. The labeled streptavidin binding peptide- 
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tagged peptide was incubated with a range of streptavidin 
concentrations for 1 hour before being transferred to a 
streptavidin-coated plate and incubated for five minutes. The 
labeled peptide not bound to the plate was pipetted off. The 
binding affinity was measured by competition with varying 5 
concentrations of streptavidin. Analysis of the binding curve 
Strep-tag I1 contain the tripeptide motif HPQ, but the 
flanking sequence in the streptavidin binding peptide-tag 
presumably provides additional favorable contacts with 
streptavidin, 
Other Embodiments 
gave a Kd Of 2.4+1-0.1 nM. 15)(2.4 nM; et 
proc. Natz. Acad. sei. USA 98:3750-3755, 2o01). The 
streptavidin binding peptide-tag therefore bound to strepta- 
From the foregoing description, it will be apparent that 
variations and modifications may be made to the invention 
described herein to adopt it to various usages and conditions, vidin with a -5,000-fold higher affinity than does the Strep- i o  Such embodiments are also within the scope of the follow- tag I1 (Schmidt et al. J.  Mol. Biol. 255:753-66, 1996). This 
higher affinity accounts for the fact that, after extensive ing 
washing (with 80 volumes), the yield of retained All publications mentioned in this specification are herein 
peptide using the streptavidin binding peptide-tag was incorporated by reference to the same extent as if each 
2,200-fold higher than the yield using the Strep-tag 11 15 independent publication or patent application was specifi- 
(Wilson et al. Proc. Natl. Acad. Sci. USA 98:375&3755, cally and individually indicated to be incorporated by ref- 
2001). Both the streptavidin binding peptide-tag and the erence. 
<160>  
<210>  
<211>  
<212>  
<213>  
<220> 
<223>  
<400>  
SEQUENCE L I S T I N G  
NUMBER OF SEQ I D  NOS: 4 1  
SEQ I D  NO 1 
LENGTH: 1 0 1  
TYPE: PRT 
ORGANISM: A r t i f i c i a l  Sequence 
FEATURE : 
OTHER INFORMATION: selected pept ide  
SEQUENCE: 1 
M e t  A s p  G l u  L y s  T h r  H i s  C y s  T h r  I l e  Ser M e t  A s n  G l y  A l a  V a l  P r o  
1 5 1 0  1 5  
L e u  V a l  P r o  H i s  H i s  H i s  P ro  G l n  G l y  A s p  P r o  L e u  A r g  L e u  L e u  H i s  
20  2 5  3 0  
A r g  P r o  G l n  P r o  A l a  L e u  L e u  V a l  A r g  H i s  P r o  G l n  G l y  A s p  L e u  V a l  
3 5  4 0  4 5  
A l a  L e u  V a l  G l u  H i s  H i s  G l u  G l y  V a l  A s p  A r g  G l y  L e u  V a l  A l a  L e u  
5 0  5 5  60  
Pro  G l u  L e u  H i s  A l a  G l u  G l u  L e u  G l y  G l u  P r o  V a l  G l y  A s p  L e u  V a l  
65  7 0  75  8 0  
G l n  G l y  P r o  V a l  G l u  G l n  V a l  G l n  G l y  V a l  V a l  A s p  A l a  L e u  V a l  T r p  
85  9 0  9 5  
A r g  L e u  P r o  P r o  Ser 
1 0 0  
<210>  
<211>  
<212>  
<213>  
<220> 
<223>  
<400>  
SEQ I D  NO 2 
LENGTH: 1 0 1  
TYPE: PRT 
ORGANISM: A r t i f i c i a l  Sequence 
FEATURE : 
OTHER INFORMATION: selected pept ide  
SEQUENCE: 2 
M e t  A s p  G l u  L y s  T h r  H i s  C y s  Phe H i s  P r o  G l y  A s p  H i s  L e u  V a l  A r g  
1 5 1 0  1 5  
L e u  V a l  G l u  G l u  L e u  G l n  A l a  L e u  A l a  G l u  G l y  L e u  G l n  A r g  G l n  G l y  
20  2 5  3 0  
G l y  A r g  G l n  P r o  H i s  A r g  L e u  P r o  A r g  A r g  A r g  P r o  H i s  H i s  L e u  G l n  
3 5  4 0  4 5  
L e u  L e u  L e u  A s p  G l u  A l a  H i s  P r o  G l n  A l a  G l y  P r o  L e u  A r g  G l u  A r g  
5 0  5 5  60  
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- con t inued  
A l a  H i s  G l n  V a l  A s p  G l y  A r g  L e u  L e u  L e u  G l n  H i s  H i s  P r o  G l n  G l y  
6 5  7 0  7 5  8 0  
A s p  A r g  L e u  L e u  G l n  G l n  P r o  G l n  A s p  H i s  P ro  L e u  G l u  L e u  V a l  T r p  
8 5  9 0  95  
A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 3 
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 3 
M e t  T h r  A r g  A r g  P r o  T h r  A l a  S e r  S e r  S e r  S e r  C y s  V a l  A r g  H i s  L e u  
1 5 1 0  1 5  
L e u  L e u  A r g  G l n  G l y  G l u  H i s  G l y  H i s  G l n  A l a  L e u  G l u  A s p  A r g  A s p  
20  2 5  3 0  
L y s  A l a  A r g  H i s  V a l  A r g  L e u  V a l  G l u  G l y  A s p  V a l  G l u  V a l  L e u  G l y  
35  40 45 
G l y  L e u  A s p  A r g  L e u  A l a  A r g  A l a  A r g  H i s  G l u  A l a  L e u  H i s  P r o  G l n  
5 0  5 5  6 0  
A l a  G l y  L e u  V a l  H i s  L e u  P r o  L e u  H i s  G l y  G l y  A s p  L e u  G l y  G l y  H i s  
6 5  7 0  7 5  8 0  
L e u  A r g  L e u  V a l  L e u  G l u  A l a  H i s  P r o  G l n  G l y  A s p  A r g  L e u  G l y  L e u  
8 5  9 0  95  
A l a  V a l  H i s  H i s  H i s  
1 0 0  
<210>  SEQ I D  NO 4 
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 4 
M e t  A s p  G l u  L y s  T h r  H i s  T r p  G l y  I l e  S e r  T h r  T r p  A r g  G l y  G l u  P r o  
1 5 1 0  1 5  
L e u  L e u  H i s  H i s  P r o  G l n  A l a  G l y  A r g  L e u  P ro  L e u  A s p  A r g  A r g  A r g  
20  2 5  3 0  
A l a  A r g  H i s  A r g  A r g  I l e  L e u  G l y  A l a  G l u  P ro  G l y  G l y  V a l  A s p  H i s  
35  40 45 
G l y  L e u  A r g  L e u  G l u  L e u  L e u  A s p  A s p  H i s  A r g  P r o  L e u  V a l  P r o  A s p  
5 0  5 5  6 0  
H i s  H i s  P r o  G l n  A r g  G l y  P r o  L e u  G l n  A r g  G l y  A s p  L e u  P r o  G l n  V a l  
6 5  7 0  7 5  8 0  
V a l  P r o  L e u  V a l  A r g  L e u  A r g  H i s  A l a  H i s  V a l  L e u  G l y  L e u  G l y  L e u  
8 5  9 0  95  
A l a  A l a  A l a  T h r  I l e  T h r  
1 0 0  
<210>  SEQ I D  NO 5 
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
US 7,138,253 B2 
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- con t inued  
<400>  SEQUENCE: 5 
M e t  A s p  G l u  L y s  T h r  H i s  T r p  V a l  A s n  V a l  T y r  H i s  P r o  G l n  G l y  A s p  
1 5 1 0  1 5  
L e u  L e u  V a l  A r g  G l y  H i s  G l y  H i s  A s p  V a l  G l u  A l a  L e u  H i s  A s p  G l n  
20  2 5  3 0  
G l y  L e u  H i s  G l n  L e u  A s p  L e u  L e u  V a l  G l y  P ro  P r o  P r o  G l u  V a l  V a l  
35  40 45 
A r g  A l a  L e u  A r g  G l y  G l u  V a l  L e u  G l y  G l y  L e u  A r g  A r g  L e u  V a l  P r o  
5 0  5 5  6 0  
L e u  A s p  H i s  P r o  G l n  G l y  G l u  A l a  L e u  A s p  G l n  A l a  A r g  G l n  A r g  P r o  
6 5  7 0  7 5  8 0  
G l n  H i s  L e u  L e u  G l u  L e u  H i s  H i s  A r g  A l a  L e u  P r o  P r o  A l a  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 6 
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 6 
M e t  A s p  G l u  L y s  T h r  H i s  T r p  L e u  A s n  A s n  Phe G l u  G l u  L e u  L e u  A l a  
1 5 1 0  1 5  
A r g  L e u  A s p  G l y  L e u  A r g  G l u  G l y  G l u  A s p  H i s  P r o  L e u  V a l  L e u  A r g  
20  2 5  3 0  
H i s  H i s  P r o  G l n  G l y  A s p  G l y  L e u  L e u  A s p  G l n  P r o  L e u  G l y  A r g  H i s  
35  40 45 
A r g  A l a  L e u  A s p  G l y  G l u  V a l  A r g  G l u  G l y  A s p  A r g  P r o  L e u  A s p  G l n  
5 0  5 5  6 0  
G l y  G l y  G l u  G l u  A s p  L e u  G l y  A l a  L e u  V a l  A s p  A s p  A s p  G l y  G l u  V a l  
6 5  7 0  7 5  8 0  
L e u  A s p  G l y  L e u  V a l  H i s  V a l  G l y  V a l  H i s  V a l  H i s  A s p  P r o  L e u  V a l  
8 5  9 0  95  
C y s  G l y  C y s  H i s  H i s  H i s  
1 0 0  
<210>  SEQ I D  NO 7 
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 7 
M e t  A s p  G l u  L y s  T h r  H i s  T r p  Phe G l y  T h r  L e u  A s n  S e r  Phe P r o  T h r  
1 5 1 0  1 5  
H i s  T r p  M e t  S e r  A l a  V a l  G l y  A s n  G l y  L y s  I l e  A s p  C y s  S e r  Phe A s n  
20  2 5  3 0  
M e t  A s n  L e u  S e r  L e u  A s n  H i s  T r p  L e u  S e r  S e r  G l y  H i s  P r o  A s p  G l y  
35  40 45 
A l a  L e u  A s p  A s p  G l n  L e u  H i s  P r o  G l n  G l y  A s p  A l a  L e u  V a l  G l y  A r g  
5 0  5 5  6 0  
A s p  A s p  G l y  V a l  V a l  G l n  A l a  L e u  A r g  L e u  G l u  G l y  G l n  H i s  G l n  H i s  
6 5  7 0  7 5  8 0  
US 7,138,253 B2 
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- con t inued  
A r g  A r g  L e u  A l a  G l n  A r g  A r g  A l a  A s p  A r g  H i s  A r g  G l n  L e u  V a l  T r p  
8 5  9 0  9 5  
A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210> SEQ I D  NO 8 
<211> LENGTH: 1 0 2  
<212> TYPE: PRT 
<213> ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223> OTHER INFORMATION: selected pept ide  
<400> SEQUENCE: 8 
M e t  A s p  G l u  L y s  T h r  H i s  C y s  T h r  I l e  G l u  L e u  A s n  Phe S e r  Phe T h r  
1 5 1 0  1 5  
H i s  T r p  L y s  L e u  H i s  H i s  H i s  P r o  G l n  G l y  A s p  A l a  L e u  L e u  A s p  A s p  
20  2 5  3 0  
G l y  V a l  A r g  P r o  H i s  H i s  P r o  L e u  A l a  A s p  G l u  G l y  G l y  G l y  L e u  A s p  
3 5  40  45  
G l n  G l y  L e u  G l y  H i s  A r g  A r g  G l y  V a l  V a l  A l a  G l u  A r g  L e u  A l a  A r g  
5 0  5 5  6 0  
A r g  A s p  P r o  G l u  V a l  L e u  G l u  G l y  L e u  V a l  G l u  A r g  H i s  A r g  G l y  L e u  
6 5  7 0  7 5  8 0  
V a l  P r o  A r g  L e u  A r g  H i s  G l y  G l y  G l u  A r g  H i s  A l a  G l u  P r o  L e u  V a l  
8 5  9 0  9 5  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210> SEQ I D  NO 9 
<211> LENGTH: 1 0 2  
<212> TYPE: PRT 
<213> ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223> OTHER INFORMATION: selected pept ide  
<400> SEQUENCE: 9 
M e t  A s p  G l u  L y s  T h r  H i s  C y s  A s n  T h r  G l y  L e u  T y r  A s p  G l y  A l a  A l a  
1 5 1 0  1 5  
A s p  C y s  Phe A s n  G l u  L e u  A s n  L y s  A s p  V a l  A l a  P r o  L e u  V a l  G l u  G l y  
20  2 5  3 0  
A r g  H i s  A s p  L e u  V a l  G l u  G l y  L e u  L e u  L e u  G l u  A r g  H i s  P r o  G l n  G l y  
3 5  40  45  
A s p  P r o  L e u  V a l  A l a  H i s  A r g  G l n  L e u  V a l  H i s  H i s  P r o  L e u  L e u  G l y  
5 0  5 5  6 0  
A r g  G l y  G l u  A r g  H i s  A r g  A r g  A l a  L e u  V a l  P ro  G l n  G l n  G l u  H i s  G l n  
6 5  7 0  7 5  8 0  
P r o  H i s  A r g  L e u  G l n  P r o  V a l  V a l  A s p  L e u  G l y  A r g  A r g  A r g  L e u  V a l  
8 5  9 0  9 5  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210> SEQ I D  NO 1 0  
<211> LENGTH: 1 0 3  
<212> TYPE: PRT 
<213> ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223> OTHER INFORMATION: selected pept ide  
<400> SEQUENCE: 1 0  
M e t  A s p  G l u  L y s  T h r  H i s  T r p  H i s  G l u  A r g  A l a  G l n  G l u  L e u  V a l  G l y  
US 7,138,253 B2 
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- con t inued  
1 5 1 0  1 5  
G l y  L e u  L e u  L e u  H i s  A s p  H i s  P r o  G l n  A r g  L e u  L e u  L e u  G l u  P r o  A r g  
20  2 5  3 0  
G l y  P r o  A r g  P r o  L e u  A r g  G l y  L e u  V a l  H i s  G l u  A r g  G l y  H i s  G l n  P r o  
35  40 45 
G l n  P r o  L e u  A l a  G l y  A r g  V a l  G l u  G l u  A l a  A s p  G l y  G l y  L e u  L e u  A r g  
5 0  5 5  6 0  
A s p  G l y  G l y  G l y  G l u  L e u  G l u  P r o  L e u  V a l  A r g  G l u  G l y  G l u  A s p  H i s  
6 5  7 0  7 5  8 0  
L e u  G l u  P r o  L e u  A s p  A s p  G l u  L e u  A s p  A l a  G l y  P r o  A r g  G l y  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  H i s  H i s  H i s  
1 0 0  
<210>  SEQ I D  NO 11 
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 1  
M e t  A s p  G l u  Lys T h r  H i s  T r p  H i s  G l u  A r g  V a l  H i s  H i s  L e u  A l a  A s p  
1 5 1 0  1 5  
G l y  L e u  G l u  G l n  H i s  P r o  G l n  G l y  G l n  A r g  A r g  P r o  L e u  V a l  G l u  A r g  
20  2 5  3 0  
H i s  A r g  G l n  V a l  P r o  A r g  G l y  L e u  V a l  A r g  G l u  L e u  G l n  H i s  G l u  G l y  
35  40 45 
L e u  P r o  L e u  G l u  H i s  P r o  A l a  G l y  V a l  H i s  V a l  I l e  A r g  L e u  H i s  G l n  
5 0  5 5  6 0  
G l y  A s p  A s p  A r g  A s p  V a l  A s p  G l y  L e u  V a l  A s p  G l y  H i s  G l y  A r g  A s p  
6 5  7 0  7 5  8 0  
V a l  A r g  G l y  L e u  G l u  A r g  G l u  V a l  G l y  A s p  G l y  P r o  H i s  A r g  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 2  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 2  
M e t  A s p  Lys A s p  P r o  L e u  L e u  G l u  G l u  L e u  G l u  G l u  L e u  A r g  G l u  A r g  
1 5 1 0  1 5  
L e u  V a l  H i s  H i s  P r o  G l n  G l y  G l y  L e u  L e u  P ro  L e u  A r g  G l y  G l n  V a l  
20  2 5  3 0  
G l y  H i s  A s p  A l a  G l u  A r g  L e u  G l y  A l a  G l u  V a l  A s p  A s p  L e u  A r g  G l y  
35  40 45 
G l y  L e u  L e u  A s p  G l u  P r o  G l n  A r g  A l a  V a l  A l a  G l y  L e u  H i s  H i s  V a l  
5 0  5 5  6 0  
P r o  H i s  A r g  V a l  G l y  G l n  A r g  L e u  V a l  H i s  G l u  V a l  A r g  G l u  L e u  A s p  
6 5  7 0  7 5  8 0  
G l u  G l y  L e u  L e u  A s p  G l n  A r g  A s p  A s p  L e u  A r g  G l n  A r g  L e u  V a l  T r p  
8 5  9 0  95  
US 7,138,253 B2 
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- con t inued  
A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 3  
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 3  
M e t  G l u  A r g  G l u  A s p  P r o  L e u  A s p  G l u  G l n  L e u  A r g  G l u  L e u  A r g  G l u  
1 5 1 0  1 5  
A l a  L e u  V a l  A s p  H i s  P r o  G l n  G l y  G l y  A l a  G l n  A l a  L e u  H i s  A r g  H i s  
20  2 5  3 0  
A s p  G l y  G l y  G l u  H i s  V a l  P r o  L e u  A r g  A r g  V a l  G l n  H i s  A r g  L e u  G l n  
35  40 45 
P r o  G l y  L e u  G l n  H i s  H i s  L e u  G l u  P r o  G l n  P ro  L e u  G l y  L e u  L e u  G l y  
5 0  5 5  6 0  
G l u  L e u  G l n  A l a  A r g  L e u  G l n  P r o  L e u  A l a  G l y  G l u  H i s  G l u  G l y  A s p  
6 5  7 0  7 5  8 0  
G l y  A l a  G l y  L e u  G l n  A r g  V a l  P r o  G l y  H i s  G l n  G l y  A r g  A r g  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 4  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 4  
M e t  A s p  G l u  L y s  T h r  H i s  A r g  T h r  L e u  S e r  V a l  S e r  L e u  S e r  Phe A s n  
1 5 1 0  1 5  
A s p  T r p  L e u  G l y  G l n  T h r  L y s  A l a  C y s  T r p  A r g  L e u  V a l  G l u  G l y  L e u  
20  2 5  3 0  
H i s  G l y  H i s  P r o  G l n  G l y  L e u  V a l  A r g  G l u  H i s  G l u  V a l  A s p  V a l  L e u  
35  40 45 
P r o  L e u  A l a  G l u  G l u  V a l  G l n  G l n  V a l  V a l  G l y  G l y  L e u  A l a  A s p  G l y  
5 0  5 5  6 0  
V a l  G l u  G l n  P r o  G l y  G l y  G l y  L e u  L e u  H i s  A r g  A l a  G l n  A r g  V a l  A s p  
6 5  7 0  7 5  8 0  
H i s  P r o  L e u  P r o  A s p  H i s  A l a  G l y  G l n  V a l  L e u  G l y  A r g  L e u  V a l  T r p  
8 5  9 0  95  
A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 5  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 5  
M e t  A s p  G l u  L y s  T h r  H i s  T r p  L e u  G l u  A s p  L e u  L y s  G l y  V a l  L e u  L y s  
1 5 1 0  1 5  
A s p  C y s  L e u  L y s  A s p  L e u  M e t  A s p  Phe T h r  L y s  A s p  C y s  A r g  S e r  P r o  
US 7,138,253 B2 
37 38 
- con t inued  
<210>  SEQ I D  NO 1 8  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 8  
M e t  A s p  G l u  L y s  T h r  H i s  C y s  A l a  V a l  A s n  V a l  A s n  V a l  G l y  L e u  T h r  
1 5 1 0  1 5  
H i s  T r p  C y s  H i s  A r g  V a l  A l a  H i s  L e u  G l n  P ro  L e u  A s p  P r o  H i s  P r o  
20  2 5  3 0  
G l n  G l y  A s p  H i s  L e u  A r g  L e u  G l u  P r o  L e u  G l y  H i s  A l a  L e u  V a l  A s p  
35  40 45 
P r o  L e u  V a l  G l n  G l y  V a l  G l u  G l u  V a l  V a l  A r g  P r o  L e u  G l n  L e u  A s p  
5 0  5 5  6 0  
V a l  G l y  V a l  G l n  A r g  V a l  A l a  L e u  V a l  G l u  G l n  V a l  A l a  G l u  V a l  G l y  
6 5  7 0  7 5  8 0  
G l u  G l y  L e u  A s p  H i s  G l u  A l a  G l y  G l n  A l a  H i s  G l y  A l a  L e u  V a l  T r p  
8 5  9 0  95  
A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 1 9  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 1 9  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  A s p  V a l  A s p  G l u  
35  40 45 
G l y  L e u  V a l  G l n  A s p  L e u  H i s  G l y  V a l  V a l  A l a  G l y  L e u  L e u  A s p  P r o  
5 0  5 5  6 0  
V a l  G l u  L y s  L e u  L e u  T h r  A s p  T r p  Phe L y s  L y s  Phe L y s  A s n  V a l  S e r  
6 5  7 0  7 5  8 0  
L y s  A s p  C y s  L y s  M e t  T h r  Phe T y r  L e u  G l u  M e t  T y r  A s p  T r p  S e r  G l y  
8 5  9 0  95  
G l y  C y s  H i s  H i s  H i s  
1 0 0  
<210>  SEQ I D  NO 2 0  
<211>  LENGTH: 1 0 2  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 0  
M e t  A s n  G l u  L y s  T h r  H i s  C y s  L y s  L e u  A s n  Phe L y s  V a l  A s n  I l e  A l a  
1 5 1 0  1 5  
A s p  T r p  L e u  A l a  G l u  Phe H i s  G l y  G l y  G l y  G l n  G l y  L e u  L e u  G l y  A r g  
20  2 5  3 0  
A r g  A s p  G l y  V a l  V a l  G l n  A r g  L e u  V a l  A s p  G l y  V a l  G l n  G l u  A r g  V a l  
US 7,138,253 B2 
39 40 
- con t inued  
35  40 45 
G l u  A r g  L e u  A s p  A r g  A s p  P r o  G l y  L e u  G l y  A s p  L e u  A r g  L e u  G l u  L e u  
5 0  5 5  6 0  
H i s  H i s  A r g  A s p  H i s  A r g  L e u  A r g  L e u  G l y  G l y  G l u  H i s  L e u  L e u  A r g  
6 5  7 0  7 5  8 0  
A s p  H i s  P r o  L e u  G l u  P r o  A s p  A s p  H i s  L e u  V a l  V a l  G l y  G l y  L e u  V a l  
8 5  9 0  95  
T r p  A r g  L e u  P r o  P r o  S e r  
1 0 0  
<210>  SEQ I D  NO 2 1  
<211>  LENGTH: 1 0 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 1  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  A s p  V a l  A s p  G l u  
35  40 45 
G l y  L e u  V a l  G l n  A s p  L e u  H i s  G l y  V a l  V a l  A l a  G l y  L e u  L e u  A s p  P r o  
5 0  5 5  6 0  
V a l  G l u  L y s  L e u  L e u  T h r  A s p  T r p  Phe L y s  L y s  Phe L y s  A s n  V a l  S e r  
6 5  7 0  7 5  8 0  
L y s  A s p  C y s  L y s  M e t  T h r  Phe T y r  L e u  G l u  M e t  T y r  A s p  T r p  S e r  G l y  
8 5  9 0  95  
G l y  C y s  L y s  L e u  G l y  
1 0 0  
<210>  SEQ I D  NO 2 2  
<211>  LENGTH: 89  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 2  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  A s p  V a l  A s p  G l u  
35  40 45 
G l y  L e u  V a l  G l n  A s p  L e u  H i s  G l y  V a l  V a l  A l a  G l y  L e u  L e u  A s p  P r o  
5 0  5 5  6 0  
V a l  G l u  L y s  L e u  L e u  T h r  A s p  T r p  Phe L y s  L y s  Phe L y s  A s n  V a l  S e r  
6 5  7 0  7 5  8 0  
M e t  M e t  S e r  G l y  G l y  C y s  L y s  L e u  G l y  
8 5  
<210>  SEQ I D  NO 2 3  
<211>  LENGTH: 75  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
US 7,138,253 B2 
42 
- con t inued  
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 3  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  A s p  V a l  A s p  G l u  
35  40 45 
G l y  L e u  V a l  G l n  A s p  L e u  H i s  G l y  V a l  V a l  A l a  G l y  L e u  L e u  A s p  P r o  
5 0  5 5  6 0  
V a l  G l u  M e t  M e t  Ser G l y  G l y  C y s  L y s  L e u  G l y  
6 5  7 0  7 5  
<210>  SEQ I D  NO 2 4  
<211>  LENGTH: 6 1  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 4  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  A s p  V a l  A s p  G l u  
35  40 45 
G l y  L e u  V a l  G l n  M e t  M e t  Ser G l y  G l y  C y s  L y s  L e u  G l y  
5 0  5 5  6 0  
<210>  SEQ I D  NO 2 5  
<211>  LENGTH: 47 
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 5  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20  2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  M e t  M e t  Ser G l y  G l y  C y s  L y s  L e u  G l y  
35  40 45 
<210>  SEQ I D  NO 2 6  
<211>  LENGTH: 47 
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: selected pept ide  
<400>  SEQUENCE: 2 6  
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  1 5  
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  G l y  
20  2 5  3 0  
A l a  G l y  G l n  A r g  G l u  P r o  M e t  M e t  Ser G l y  G l y  C y s  L y s  L e u  G l y  
35  40 45 
US 7,138,253 B2 
43 44 
- con t inued  
< 2 1 0 >  SEQ I D  NO 2 7  
< 2 1 1 >  LENGTH: 3 9  
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: selected pept ide  
< 4 0 0 >  SEQUENCE: 2 7  
M e t  A s p  G l y  H i s  V a l  V a l  G l u  G l y  L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  
1 5 1 0  15 
A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  G l n  G l y  G l n  A r g  G l u  P r o  M e t  M e t  
20  2 5  3 0  
S e r  G l y  G l y  C y s  L y s  L e u  G l y  
3 5  
< 2 1 0 >  SEQ I D  NO 2 8  
< 2 1 1 >  LENGTH: 8 9  
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: selected pept ide  
< 4 0 0 >  SEQUENCE: 2 8  
M e t  A s p  G l u  G l y  L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  
1 5 1 0  15 
G l u  H i s  H i s  P r o  G l n  G l y  G l n  A r g  G l u  P r o  L e u  V a l  G l n  G l u  V a l  G l u  
20  2 5  3 0  
A s p  V a l  A s p  G l u  G l y  L e u  V a l  G l n  A s p  L e u  H i s  G l y  V a l  V a l  A l a  G l y  
3 5  4 0  4 5  
L e u  L e u  A s p  P r o  V a l  G l u  L y s  L e u  L e u  T h r  A s p  T r p  Phe L y s  L y s  Phe 
5 0  55 6 0  
L y s  A s n  V a l  S e r  L y s  A s p  C y s  L y s  M e t  T h r  Phe T y r  L e u  G l u  M e t  T y r  
6 5  7 0  7 5  8 0  
A s p  T r p  S e r  G l y  G l y  C y s  L y s  L e u  G l y  
8 5  
< 2 1 0 >  SEQ I D  NO 2 9  
< 2 1 1 >  LENGTH: 2 9  
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: selected pept ide  
< 4 0 0 >  SEQUENCE: 2 9  
M e t  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  G l n  G l y  
1 5 1 0  15 
G l n  A r g  G l u  P r o  M e t  M e t  S e r  G l y  G l y  C y s  L y s  L e u  G l y  
20  2 5  
< 2 1 0 >  SEQ I D  NO 3 0  
< 2 1 1 >  LENGTH: 3 5  
< 2 1 2 >  TYPE: DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: 3 0  
a tagccggtg  ccaagct tgc  agccgccaga ccagt  3 5  
< 2 1 0 >  SEQ I D  NO 3 1  
< 2 1 1 >  LENGTH: 3 5  
< 2 1 2 >  TYPE: DNA 
US 7,138,253 B2 
46 
- con t inued  
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: p r i m e r  
< 4 0 0 >  SEQUENCE: 3 1  
acuggucugg cggcugcaag cuuggcaccg gcuau 
< 2 1 0 >  SEQ I D  NO 3 2  
< 2 1 1 >  LENGTH: 1 4  
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: selected pept ide  
< 4 0 0 >  SEQUENCE: 3 2  
T r p  Ser G l y  G l y  C y s  H i s  H i s  H i s  H i s  H i s  H i s  Ser Ser A l a  
1 5 1 0  
< 2 1 0 >  SEQ I D  NO 33  
< 2 1 1 >  LENGTH: 11 
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: designed pept ide  
< 4 0 0 >  SEQUENCE: 33  
T r p  Ser G l y  G l y  C y s  L y s  L e u  G l y  T h r  G l y  T y r  
1 5 1 0  
< 2 1 0 >  SEQ I D  NO 3 4  
< 2 1 1 >  LENGTH: 4 4  
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: designed pept ide  
< 4 0 0 >  SEQUENCE: 3 4  
M e t  A s p  G l u  A l a  H i s  P r o  G l n  A l a  G l y  P r o  V a l  A s p  G l n  A l a  A s p  A l a  
1 5 1 0  15 
A r g  L e u  V a l  G l n  G l n  G l y  A l a  L e u  G l n  H i s  H i s  P r o  G l n  G l y  A s p  A r g  
20 2 5  3 0  
M e t  M e t  Ser G l y  G l y  C y s  L y s  L e u  G l y  T h r  G l y  T y r  
35 4 0  
< 2 1 0 >  SEQ I D  NO 35 
< 2 1 1 >  LENGTH: 38 
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: selected pept ide  
< 4 0 0 >  SEQUENCE: 35 
M e t  A s p  G l u  L y s  T h r  T h r  G l y  T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  
1 5 1 0  15 
L e u  A l a  G l y  G l u  L e u  G l u  G l n  L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  
20 2 5  3 0  
G l n  G l y  G l n  A r g  G l u  P r o  
35 
35 
< 2 1 0 >  SEQ I D  NO 3 6  
< 2 1 1 >  LENGTH: 9 
< 2 1 2 >  TYPE: PRT 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: designed pept ide  
US 7,138,253 B2 
48 
- con t inued  
<400>  SEQUENCE: 3 6  
Met Met Ser Gly Gly Cys Lys Leu Gly 
1 5 
<210>  SEQ ID NO 3 7  
<211>  LENGTH: 6 6 8 8  
<212>  TYPE: DNA 
<213>  ORGANISM: Artificial Sequence 
<220>  FEATURE: 
<223>  OTHER INFORMATION: plasmid 
<400>  SEQUENCE: 3 7  
atccggatat agttcctcct ttcagcaaaa aacccctcaa gacccgttta gaggccccaa 
ggggttatgc tagttattgc tcagcggtgg cagcagccaa ctcagcttcc tttcgggctt 
tgttagcagc cggatctcag tggtggtggt ggtggtgctc gagtgcggcc gcaagctttt 
agtcgtcatg tccatgatag gtgtcgtccc cgatatcaat gctattgtta aagcaggtct 
tacacatgtt atagatcctc aaatgcttgt tcttcacctt ccagttccgg ggagccacct 
tgcatttcac acaagggtcc atgctacctc ggggtaccaa gaattcgtga tgatggtgat 
ggtgaccgga tcctggttca cgttgacctt gtgggtgatg ctccagtcgt gcacgaagtt 
gttcaagttc cccagccagt ccttcaacaa cgtgtccacc tcgccaacca gtggtcttct 
cgtccatccc tgagccgcta cctcctgagc tcgaattagt ctgcgcgtct ttcagggctt 
catcgacagt ctgacgaccg ctggcggcgt tgatcaccgc agtacgcacg gcataccaga 
aagcggacat ctgcgggatg ttcggcatga tttcaccttt ctgggcgttt tccattgtgg 
cggcaatacg tggatctttc gccaactctt cctcgtaaga cttcagcgct acggcaccca 
gcggtttgtc tttattaacc gcttccagac cttcatcagt cagcagatag ttttcgagga 
actcttttgc cagctctttg ttcggactgg cggcgttaat acctgcgctc agcacgccaa 
cgaacggttt ggatggttga cccttgaagg tcggcagtac cgttacacca taattcactt 
tgctggtgtc gatgttggac catgcccacg ggccgttgat ggtcatcgct gtttcgcctt 
tattaaaggc agcttctgcg atggagtaat cggtgtctgc attcatgtgt ttgtttttaa 
tcaggtcaac caggaaggtc agacccgctt tcgcgccagc gttatccacg cccacgtctt 
taatgtcgta cttgccgttt tcatacttga acgcataacc cccgtcagca gcaatcagcg 
gccaggtgaa gtacggttct tgcaggttga acatcagcgc gctcttacct ttcgctttca 
gttctttatc cagcgccggg atctcttccc aggtttttgg cgggttcggc agcagatctt 
tgttataaat cagcgataac gcttcaacag cgatcgggta agcaatcagc ttgccgttgt 
aacgtacggc atcccaggta aacggataca gcttgtcctg gaacgctttg tccggggtga 
tttcagccaa caggccagat tgagcgtagc caccaaagcg gtcgtgtgcc cagaagataa 
tgtcagggcc atcgccagtt gccgcaacct gtgggaattt ctcttccagt ttatccggat 
gctcaacggt gactttaatt ccggtatctt tctcgaattt cttaccgact tcagcgagac 
cgttatagcc tttatcgccg ttaatccaga ttaccagttt accttcttcg attcccatgg 
tatatctcct tcttaaagtt aaacaaaatt atttctagag gggaattgtt atccgctcac 
aattccccta tagtgagtcg tattaatttc gcgggatcga gatctcgatc ctctacgccg 
gacgcatcgt ggccqqcatc accggcgcca caggtgcggt tgctggcgcc tatatcgccg 
acatcaccga tggggaagat cgggctcgcc acttcgggct catgagcgct tgtttcggcg 
tgggtatggt ggcaggcccc gtggccgggg gactgttggg cgccatctcc ttgcatgcac 
6 0  
1 2 0  
1 8 0  
2 4 0  
3 0 0  
3 6 0  
4 2 0  
4 8 0  
5 4 0  
6 0 0  
6 6 0  
7 2 0  
7 8 0  
8 4 0  
9 0 0  
9 6 0  
1 0 2 0  
1 0 8 0  
1 1 4 0  
1 2 0 0  
1 2 6 0  
1 3 2 0  
1 3 8 0  
1 4 4 0  
1 5 0 0  
1 5 6 0  
1 6 2 0  
1 6 8 0  
1 7 4 0  
1 8 0 0  
1 8 6 0  
1 9 2 0  
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50 
- con t inued  
c a t t c c t t g c  ggcggcggtg ctcaacggcc t c a a c c t a c t  actgggctgc t t c c t a a t g c  
aggagtcgca taagggagag cgtcgagatc ccggacacca tcgaatggcg c a a a a c c t t t  
cgcggtatgg catgatagcg cccggaagag a g t c a a t t c a  gggtggtgaa tg tgaaacca 
g t a a c g t t a t  acgatgtcgc agagtatgcc g g t g t c t c t t  a tcagaccgt  t t c c c g c g t g  
gtgaaccagg ccagccacgt t t c t g c g a a a  acgcgggaaa aagtggaagc ggcgatggcg 
gagc tgaat t  aca t tcccaa ccgcgtggca caacaactgg cgggcaaaca g t c g t t g c t g  
a t t g g c g t t g  ccacctccag t c t g g c c c t g  cacgcgccgt c g c a a a t t g t  cgcggcgat t  
aaatc tcgcg ccgatcaact  gggtgccagc g t g g t g g t g t  cgatggtaga acgaagcggc 
gtcgaagcct  gtaaagcggc ggtgcacaat  c t t c t c g c g c  aacgcgtcag tgggc tga tc  
a t t a a c t a t c  cgctggatga ccaggatgcc a t t g c t g t g g  aagc tgcc tg  c a c t a a t g t t  
c c g g c g t t a t  t t c t t g a t g t  c tc tgaccag acacccatca a c a g t a t t a t  t t t c t c c c a t  
gaagacggta cgcgactggg cgtggagcat  c t g g t c g c a t  tgggtcacca gcaaatcgcg 
c t g t t a g c g g  gcccat taag t t c t g t c t c g  gcgcgtc tgc g t c t g g c t g g  c tggcataaa 
t a t c t c a c t c  gcaatcaaat  tcagccgata gcggaacggg aaggcgactg gagtgccatg 
t c c g g t t t t c  aacaaaccat gcaaatgctg aatgagggca t c g t t c c c a c  t g c g a t g c t g  
gt tgccaacg atcagatggc gctgggcgca atgcgcgcca t t a c c g a g t c  cgggctgcgc 
g t tgg tgcgg a t a t c t c g g t  agtgggatac gacgataccg aagacagctc a t g t t a t a t c  
ccgccgt taa  ccaccatcaa a c a g g a t t t t  cgcc tgc tgg  ggcaaaccag cgtggaccgc 
t t g c t g c a a c  t c t c t c a g g g  ccaggcggtg aagggcaatc a g c t g t t g c c  c g t c t c a c t g  
gtgaaaagaa aaaccaccct ggcgcccaat acgcaaaccg c c t c t c c c c g  cgcgt tggcc 
g a t t c a t t a a  tgcagctggc acgacaggt t  t cccgac tgg  aaagcgggca gtgagcgcaa 
cgcaat taa t  g taagt tagc  t c a c t c a t t a  ggcaccggga tc tcgaccga t g c c c t t g a g  
agcct tcaac ccagtcagct  c c t t c c g g t g  ggcgcggggc a t g a c t a t c g  tcgccgcac t  
t a t g a c t g t c  t t c t t t a t c a  t g c a a c t c g t  aggacaggtg ccggcagcgc t c t g g g t c a t  
t t t c g g c g a g  g a c c g c t t t c  gctggagcgc gacgatgatc ggcctgtcgc t t g c g g t a t t  
c g g a a t c t t g  cacgccctcg c t c a a g c c t t  c g t c a c t g g t  cccgccacca a a c g t t t c g g  
cgagaagcag g c c a t t a t c g  ccggcatggc ggccccacgg gtgcgcatga t c g t g c t c c t  
g tcg t tgagg acccggctag gctggcgggg t t g c c t t a c t  ggt tagcaga atgaatcacc 
gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaacg t c t g c g a c c t  gagcaacaac 
a tgaatgg tc  t t c g g t t t c c  g t g t t t c g t a  aagtctggaa acgcggaagt cagcgccctg 
c a c c a t t a t g  t t c c g g a t c t  gcatcgcagg a t g c t g c t g g  c t a c c c t g t g  gaacacctac 
a t c t g t a t t a  acgaagcgct ggcat tgacc c t g a g t g a t t  t t t c t c t g g t  cccgccgcat 
ccataccgcc a g t t g t t t a c  cctcacaacg t t c c a g t a a c  c g g g c a t g t t  c a t c a t c a g t  
aacccgtatc  gtgagcatcc t c t c t c g t t t  c a t c g g t a t c  a t taccccca tgaacagaaa 
t c c c c c t t a c  acggaggcat cagtgaccaa acaggaaaaa accgccc t ta  acatggcccg 
c t t t a t c a g a  agccagacat t a a c g c t t c t  ggagaaactc aacgagctgg acgcggatga 
acaggcagac a t c t g t g a a t  cgc t tcacga ccacgctgat  g a g c t t t a c c  gcagctgcct  
c g c g c g t t t c  ggtgatgacg gtgaaaacct  c tgacacatg cagctcccgg agacggtcac 
a g c t t g t c t g  taagcggatg ccgggagcag acaagcccgt cagggcgcgt cagcgggtgt  
1 9 8 0  
2 0 4 0  
2 1 0 0  
2 1 6 0  
2 2 2 0  
2 2 8 0  
2 3 4 0  
2 4 0 0  
2 4 6 0  
2 5 2 0  
2 5 8 0  
2 6 4 0  
2 7 0 0  
2 7 6 0  
2 8 2 0  
2 8 8 0  
2 9 4 0  
3 0 0 0  
3 0 6 0  
3 1 2 0  
3 1 8 0  
3 2 4 0  
3 3 0 0  
3 3 6 0  
3 4 2 0  
3 4 8 0  
3 5 4 0  
3 6 0 0  
3 6 6 0  
3 7 2 0  
3 7 8 0  
3 8 4 0  
3 9 0 0  
3 9 6 0  
4 0 2 0  
4 0 8 0  
4 1 4 0  
4 2 0 0  
4 2 6 0  
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52 
- con t inued  
tggcgggtg t  cggggcgcag ccatgaccca gtcacgtagc gatagcggag t g t a t a c t g g  
c t t a a c t a t g  cggcatcaga gcagat tg ta  ctgagagtgc a c c a t a t a t g  cggtgtgaaa 
taccgcacag atgcgtaagg agaaaatacc gcatcaggcg c t c t t c c g c t  t c c t c g c t c a  
c t g a c t c g c t  gcgctcggtc  g t tcggc tgc  ggcgagcggt a tcagctcac tcaaaggcgg 
t a a t a c g g t t  atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc 
agcaaaaggc caggaaccgt aaaaaggccg c g t t g c t g g c  g t t t t t c c a t  aggctccgcc 
cccctgacga gcatcacaaa aatcgacgct  caagtcagag gtggcgaaac ccgacaggac 
ta taaagata  c c a g g c g t t t  ccccctggaa g c t c c c t c g t  g c g c t c t c c t  g t tccgaccc  
t g c c g c t t a c  cggatacctg t c c g c c t t t c  t c c c t t c g g g  aagcgtggcg c t t t c t c a t a  
gc tcacgc tg  t a g g t a t c t c  a g t t c g g t g t  a g g t c g t t c g  c tccaagctg  ggc tg tg tgc  
acgaaccccc cgt tcagccc gaccgctgcg c c t t a t c c g g  t a a c t a t c g t  c t t g a g t c c a  
acccggtaag acacgact ta  tcgccac tgg  cagcagccac tggtaacagg at tagcagag 
cgaggta tg t  aggcggtgct  acagagt tc t  tgaagtgg tg  gcctaactac ggctacacta 
gaaggacagt a t t t g g t a t c  t g c g c t c t g c  tgaagccagt  t a c c t t c g g a  aaaagagttg 
g t a g c t c t t g  atccggcaaa caaaccaccg c tggtagcgg t g g t t t t t t t  g t t tgcaagc 
agcagattac gcgcagaaaa aaaggatctc aagaagatcc t t t g a t c t t t  t c t a c g g g g t  
c tgacgc tca  gtggaacgaa a a c t c a c g t t  a a g g g a t t t t  ggtcatgaac aataaaactg 
t c t g c t t a c a  taaacagtaa tacaaggggt g t ta tgagcc  a t a t t c a a c g  ggaaacgtc t  
t g c t c t a g g c  cgcgat taaa t t c c a a c a t g  g a t g c t g a t t  t a t a t g g g t a  taaatgggc t  
cgcgataatg tcgggcaatc aggtgcgaca a t c t a t c g a t  tg ta tgggaa gcccgatgcg 
ccagagt tg t  t t c t g a a a c a  tggcaaaggt agcgt tgcca a t g a t g t t a c  agatgagatg 
gtcagactaa actggctgac g g a a t t t a t g  c c t c t t c c g a  ccatcaagca t t t t a t c c g t  
a c t c c t g a t g  a t g c a t g g t t  ac tcaccac t  gcgatccccg ggaaaacagc a t t c c a g g t a  
t tagaagaat  a t c c t g a t t c  aggtgaaaat a t t g t t g a t g  cgctggcagt  g t t c c t g c g c  
c g g t t g c a t t  c g a t t c c t g t  t t g t a a t t g t  c c t t t t a a c a  gcgatcgcgt  a t t t c g t c t c  
gctcaggcgc aatcacgaat  gaataacggt t t g g t t g a t g  c g a g t g a t t t  tgatgacgag 
cg taa tggc t  g g c c t g t t g a  acaagtctgg aaagaaatgc a t a a a c t t t t  g c c a t t c t c a  
ccggat tcag t c g t c a c t c a  t g g t g a t t t c  t c a c t t g a t a  a c c t t a t t t t  tgacgagggg 
aaat taa tag  g t t g t a t t g a  tg t tggacga gtcggaatcg cagaccgata c c a g g a t c t t  
g c c a t c c t a t  ggaactgcct  c g g t g a g t t t  t c t c c t t c a t  tacagaaacg g c t t t t t c a a  
aaata tgg ta  t t g a t a a t c c  t g a t a t g a a t  aaat tgcagt  t t c a t t t g a t  gctcgatgag 
t t t t t c t a a g  a a t t a a t t c a  tgagcggata c a t a t t t g a a  t g t a t t t a g a  aaaataaaca 
aa taggggt t  ccgcgcacat t t ccccgaaa agtgccacct  gaaat tg taa  a c g t t a a t a t  
t t t g t t a a a a  t t c g c g t t a a  a t t t t t g t t a  aatcagctca t t t t t t a a c c  aataggccga 
aatcggcaaa a t c c c t t a t a  aatcaaaaga atagaccgag a tagggt tga  g t g t t g t t c c  
ag t t tggaac  aagagtccac ta t taaagaa cgtggactcc aacgtcaaag ggcgaaaaac 
c g t c t a t c a g  ggcgatggcc cactacgtga accatcaccc t a a t c a a g t t  t t t t g g g g t c  
gaggtgccgt  aaagcactaa atcggaaccc taaagggagc c c c c g a t t t a  gagct tgacg 
gggaaagccg gcgaacgtgg cgagaaagga agggaagaaa gcgaaaggag cgggcgctag 
ggcgctggca agtgtagcgg tcacgc tgcg  cgtaaccacc acacccgccg c g c t t a a t g c  
4 3 2 0  
4 3 8 0  
4 4 4 0  
4 5 0 0  
4 5 6 0  
4 6 2 0  
4 6 8 0  
4 7 4 0  
4 8 0 0  
4 8 6 0  
4 9 2 0  
4 9 8 0  
5 0 4 0  
5 1 0 0  
5 1 6 0  
5 2 2 0  
5 2 8 0  
5 3 4 0  
5 4 0 0  
5 4 6 0  
5 5 2 0  
5 5 8 0  
5 6 4 0  
5 7 0 0  
5 7 6 0  
5 8 2 0  
5 8 8 0  
5 9 4 0  
6 0 0 0  
6 0 6 0  
6 1 2 0  
6 1 8 0  
6 2 4 0  
6 3 0 0  
6 3 6 0  
6 4 2 0  
6 4 8 0  
6 5 4 0  
6 6 0 0  
6 6 6 0  
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- con t inued  
gccgctacag ggcgcgtccc a t t c g c c a  6 6 8 8  
<210>  SEQ I D  NO 3 8  
<211>  LENGTH: 479  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  S e q u e n c e  
<220> FEATURE: 
<223>  OTHER INFORMATION: D e s i g n e d  p r o t e i n  
<400>  SEQUENCE: 3 8  
M e t  G l y  I l e  G l u  G l u  G l y  L y s  L e u  V a l  I l e  T r p  I l e  A s n  G l y  A s p  L y s  
1 5 1 0  1 5  
G l y  T y r  A s n  G l y  L e u  A l a  G l u  V a l  G l y  L y s  L y s  Phe G l u  L y s  A s p  T h r  
20  2 5  3 0  
G l y  I l e  L y s  V a l  T h r  V a l  G l u  H i s  P r o  A s p  L y s  L e u  G l u  G l u  L y s  Phe 
35  40 45 
P r o  G l n  V a l  A l a  A l a  T h r  G l y  A s p  G l y  P r o  A s p  I l e  I l e  Phe T r p  A l a  
5 0  5 5  6 0  
H i s  A s p  A r g  Phe G l y  G l y  T y r  A l a  G l n  S e r  G l y  L e u  L e u  A l a  G l u  I l e  
6 5  7 0  7 5  8 0  
T h r  P r o  A s p  L y s  A l a  Phe G l n  A s p  L y s  L e u  T y r  P r o  Phe T h r  T r p  A s p  
8 5  9 0  95  
A l a  V a l  A r g  T y r  A s n  G l y  L y s  L e u  I l e  A l a  T y r  P r o  I l e  A l a  V a l  G l u  
1 0 0  1 0 5  1 1 0  
A l a  L e u  S e r  L e u  I l e  T y r  A s n  L y s  A s p  L e u  L e u  P r o  A s n  P r o  P r o  L y s  
1 1 5  1 2 0  1 2 5  
T h r  T r p  G l u  G l u  I l e  P r o  A l a  L e u  A s p  L y s  G l u  L e u  L y s  A l a  L y s  G l y  
1 3 0  1 3 5  1 4 0  
L y s  S e r  A l a  L e u  M e t  Phe A s n  L e u  G l n  G l u  P ro  T y r  Phe T h r  T r p  P r o  
1 4 5  1 5 0  1 5 5  1 6 0  
L e u  I l e  A l a  A l a  A s p  G l y  G l y  T y r  A l a  Phe L y s  T y r  G l u  A s n  G l y  L y s  
1 6 5  1 7 0  1 7 5  
T y r  A s p  I l e  L y s  A s p  V a l  G l y  V a l  A s p  A s n  A l a  G l y  A l a  L y s  A l a  G l y  
1 8 0  1 8 5  1 9 0  
L e u  T h r  Phe L e u  V a l  A s p  L e u  I l e  L y s  A s n  L y s  H i s  M e t  A s n  A l a  A s p  
1 9 5  2 0 0  2 0 5  
T h r  A s p  T y r  S e r  I l e  A l a  G l u  A l a  A l a  Phe A s n  L y s  G l y  G l u  T h r  A l a  
2 1 0  2 1 5  2 2 0  
M e t  T h r  I l e  A s n  G l y  P r o  T r p  A l a  T r p  S e r  A s n  I l e  A s p  T h r  S e r  L y s  
2 2 5  2 3 0  2 3 5  2 4 0  
V a l  A s n  T y r  G l y  V a l  T h r  V a l  L e u  P r o  T h r  Phe L y s  G l y  G l n  P r o  S e r  
2 4 5  2 5 0  2 5 5  
L y s  P r o  Phe V a l  G l y  V a l  L e u  S e r  A l a  G l y  I l e  A s n  A l a  A l a  S e r  P r o  
2 6 0  2 6 5  2 7 0  
A s n  L y s  G l u  L e u  A l a  L y s  G l u  Phe L e u  G l u  A s n  T y r  L e u  L e u  T h r  A s p  
2 7 5  2 8 0  2 8 5  
G l u  G l y  L e u  G l u  A l a  V a l  A s n  L y s  A s p  L y s  P ro  L e u  G l y  A l a  V a l  A l a  
2 9 0  2 9 5  3 0 0  
L e u  L y s  S e r  T y r  G l u  G l u  G l u  L e u  A l a  L y s  A s p  P r o  A r g  I l e  A l a  A l a  
3 0 5  3 1 0  3 1 5  3 2 0  
T h r  M e t  G l u  A s n  A l a  G l n  L y s  G l y  G l u  I l e  M e t  P r o  A s n  I l e  P r o  G l n  
3 2 5  3 3 0  3 3 5  
M e t  S e r  A l a  Phe T r p  T y r  A l a  V a l  A r g  T h r  A l a  V a l  I l e  A s n  A l a  A l a  
3 4 0  3 4 5  3 5 0  
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- con t inued  
S e r  Gly Arg Gln Thr Val Asp Glu Ala Leu Lys Asp Ala Gln Thr A s n  
3 5 5  3 6 0  3 6 5  
S e r  S e r  S e r  Gly Gly S e r  Gly S e r  Gly M e t  Asp Glu Lys Thr Thr G l y  
3 7 0  3 7 5  3 8 0  
Trp Arg Gly Gly H i s  Val Val Glu Gly Leu Ala Gly Glu Leu Glu G l n  
3 8 5  3 9 0  3 9 5  400  
Leu Arg Ala Arg Leu Glu H i s  H i s  P ro  Gln Gly Gln Arg Glu Pro  G l y  
4 0 5  410  4 1 5  
S e r  Gly H i s  H i s  H i s  H i s  H i s  H i s  Glu Phe Leu Val Pro  Arg Gly S e r  
420  4 2 5  4 3 0  
M e t  Asp Pro  Cys Val Lys Cys Lys Val Ala Pro Arg Asn Trp Lys Val 
4 3 5  4 4 0  4 4 5  
Lys Asn Lys H i s  Leu Arg I l e  Tyr Asn M e t  Cys Lys Thr Cys Phe A s n  
4 5 0  4 5 5  4 6 0  
Asn S e r  I l e  Asp I l e  Gly Asp Asp Thr Tyr H i s  Gly H i s  Asp Asp 
4 6 5  4 7 0  4 7 5  
<210>  SEQ I D  NO 3 9  
<211>  LENGTH: 47 
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: S e l e c t e d  p e p t i d e  
<400>  SEQUENCE: 3 9  
M e t  Asp Pro  Cys Val Lys Cys Lys Val Ala Pro Arg Asn Trp Lys Val 
1 5 1 0  1 5  
Lys Asn Lys H i s  Leu Arg I l e  Tyr Asn M e t  Cys Lys Thr Cys Phe A s n  
20  2 5  3 0  
Asn S e r  I l e  Asp I l e  Gly Asp Asp Thr Tyr H i s  Gly H i s  Asp Asp 
35  40 45 
<210>  SEQ I D  NO 4 0  
<211>  LENGTH: 6 5 4 4  
<212>  TYPE: DNA 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: plasmid 
<400>  SEQUENCE: 4 0  
a t c c g g a t a t  a g t t c c t c c t  t t c a g c a a a a  a a c c c c t c a a  g a c c c g t t t a  gaggccccaa 
g g g g t t a t g c  t a g t t a t t g c  tcagcggtgg  cagcagccaa c t c a g c t t c c  t t t c g g g c t t  
t g t t a g c a g c  c g g a t c t c a g  t g g t g g t g g t  g g t g g t g c t c  gagtgcggcc g c a a g c t t c a  
gctgcgaagc t t a t t a g a a t  t c g t g a t g a t  g g t g a t g g t g  a c c g g a t c c t  g g t t c a c g t t  
g a c c t t g t g g  g t g a t g c t c c  a g t c g t g c a c  g a a g t t g t t c  a a g t t c c c c a  g c c a g t c c t t  
caacaacgtg  t c c a c c t c g c  caaccagtgg  t c t t c t c g t c  c a t c c c t g a g  c c g c t a c c t c  
c t g a g c t c g a  a t t a g t c t g c  g c g t c t t t c a  g g g c t t c a t c  g a c a g t c t g a  cgaccgctgg 
c g g c g t t g a t  caccgcagta  cgcacggcat  accagaaagc g g a c a t c t g c  g g g a t g t t c g  
g c a t g a t t t c  a c c t t t c t g g  g c g t t t t c c a  t t g t g g c g g c  a a t a c g t g g a  t c t t t c g c c a  
a c t c t t c c t c  g t a a g a c t t c  agcgctacgg cacccagcgg t t t g t c t t t a  t t a a c c g c t t  
c c a g a c c t t c  a t c a g t c a g c  a g a t a g t t t t  cgaggaactc  t t t t g c c a g c  t c t t t g t t c g  
gactggcggc g t t a a t a c c t  gcgctcagca cgccaacgaa c g g t t t g g a t  g g t t g a c c c t  
tgaaggtcgg  c a g t a c c g t t  a c a c c a t a a t  t c a c t t t g c t  g g t g t c g a t g  t t g g a c c a t g  
6 0  
1 2 0  
1 8 0  
2 4 0  
3 0 0  
3 6 0  
4 2 0  
4 8 0  
5 4 0  
6 0 0  
6 6 0  
7 2 0  
7 8 0  
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cccacgggcc g t t g a t g g t c  a t c g c t g t t t  c g c c t t t a t t  aaaggcagct t c t g c g a t g g  
ag taa tcggt  g t c t g c a t t c  a t g t g t t t g t  t t t t a a t c a g  gtcaaccagg aaggtcagac 
c c g c t t t c g c  gccagcgt ta  tccacgccca c g t c t t t a a t  g t c g t a c t t g  c c g t t t t c a t  
act tgaacgc ataacccccg tcagcagcaa tcagcggcca ggtgaagtac g g t t c t t g c a  
gg t tgaacat  cagcgcgctc t t a c c t t t c g  c t t t c a g t t c  t t t a t c c a g c  gccgggatct  
c t t c c c a g g t  t t t t g g c g g g  t tcggcagca g a t c t t t g t t  a taaatcagc g a t a a c g c t t  
caacagcgat cgggtaagca a tcagc t tgc  c g t t g t a a c g  tacggcatcc caggtaaacg 
ga tacagc t t  g tcctggaac g c t t t g t c c g  g g g t g a t t t c  agccaacagg ccagat tgag 
cgtagccacc aaagcggtcg tg tgcccaga agataa tg tc  agggccatcg ccagt tgccg  
caacctgtgg g a a t t t c t c t  t c c a g t t t a t  ccggatgctc  aacggtgact  t t a a t t c c g g  
t a t c t t t c t c  g a a t t t c t t a  ccgac t tcag  cgagaccgt t  a t a g c c t t t a  t c g c c g t t a a  
t c c a g a t t a c  c a g t t t a c c t  t c t t c g a t t c  c c a t g g t a t a  t c t c c t t c t t  aaagttaaac 
a a a a t t a t t t  ctagagggga a t t g t t a t c c  g c t c a c a a t t  c c c c t a t a g t  g a g t c g t a t t  
a a t t t c g c g g  gatcgagatc t c g a t c c t c t  acgccggacg catcgtggcc ggcatcaccg 
gcgccacagg t g c g g t t g c t  ggcgcctata tcgccgacat  caccgatggg gaagatcggg 
c t c g c c a c t t  cgggctcatg a g c g c t t g t t  tcggcgtggg t a t g g t g g c a  ggccccgtgg 
ccgggggact g t tgggcgcc a t c t c c t t g c  a t g c a c c a t t  cc t tgcggcg gcggtgctca 
acggcctcaa c c t a c t a c t g  g g c t g c t t c c  taatgcagga gtcgcataag ggagagcgtc 
gagatcccgg acaccatcga atggcgcaaa a c c t t t c g c g  g t a t g g c a t g  atagcgcccg 
gaagagagtc aa t tcagggt  gg tgaatg tg  aaaccagtaa c g t t a t a c g a  tg tcgcagag 
t a t g c c g g t g  t c t c t t a t c a  g a c c g t t t c c  cgcgtggtga accaggccag c c a c g t t t c t  
gcgaaaacgc gggaaaaagt ggaagcggcg atggcggagc t g a a t t a c a t  tcccaaccgc 
gtggcacaac aactggcggg caaacagtcg t t g c t g a t t g  gcgt tgccac c t c c a g t c t g  
gccctgcacg cgccgtcgca a a t t g t c g c g  gcgat taaat  ctcgcgccga t c a a c t g g g t  
gccagcgtgg t g g t g t c g a t  ggtagaacga agcggcgtcg aagcctgtaa agcggcggtg 
c a c a a t c t t c  tcgcgcaacg cgtcagtggg c t g a t c a t t a  a c t a t c c g c t  ggatgaccag 
g a t g c c a t t g  ctgtggaagc t g c c t g c a c t  a a t g t t c c g g  c g t t a t t t c t  t g a t g t c t c t  
gaccagacac ccatcaacag t a t t a t t t t c  tcccatgaag acggtacgcg actgggcgtg 
gagcatc tgg t c g c a t t g g g  tcaccagcaa a t c g c g c t g t  tagcgggccc a t t a a g t t c t  
g tc tcggcgc g t c t g c g t c t  ggctggctgg ca taaata tc  tcac tcgcaa t c a a a t t c a g  
ccgatagcgg aacgggaagg cgactggagt  gcca tg tccg  g t t t t c a a c a  aaccatgcaa 
a tgc tgaatg  agggcatcgt  tcccac tgcg  a t g c t g g t t g  ccaacgatca gatggcgctg 
ggcgcaatgc gcgccat tac cgagtccggg c t g c g c g t t g  g tgcggata t  c t c g g t a g t g  
ggatacgacg ataccgaaga c a g c t c a t g t  t a t a t c c c g c  cgt taaccac catcaaacag 
g a t t t t c g c c  tgctggggca aaccagcgtg gaccgct tgc t g c a a c t c t c  tcagggccag 
gcggtgaagg gcaatcagct  g t t g c c c g t c  t c a c t g g t g a  aaagaaaaac caccctggcg 
cccaatacgc aaaccgcctc tccccgcgcg t t g g c c g a t t  c a t t a a t g c a  gctggcacga 
c a g g t t t c c c  gactggaaag cgggcagtga gcgcaacgca a t t a a t g t a a  g t t a g c t c a c  
t c a t t a g g c a  ccgggatctc  gaccgatgcc c t tgagagcc t tcaacccag t c a g c t c c t t  
ccggtgggcg cggggcatga c t a t c g t c g c  c g c a c t t a t g  a c t g t c t t c t  t t a t c a t g c a  
8 4 0  
9 0 0  
9 6 0  
1 0 2 0  
1 0 8 0  
1 1 4 0  
1 2 0 0  
1 2 6 0  
1 3 2 0  
1 3 8 0  
1 4 4 0  
1 5 0 0  
1 5 6 0  
1 6 2 0  
1 6 8 0  
1 7 4 0  
1 8 0 0  
1 8 6 0  
1 9 2 0  
1 9 8 0  
2 0 4 0  
2 1 0 0  
2 1 6 0  
2 2 2 0  
2 2 8 0  
2 3 4 0  
2 4 0 0  
2 4 6 0  
2 5 2 0  
2 5 8 0  
2 6 4 0  
2 7 0 0  
2 7 6 0  
2 8 2 0  
2 8 8 0  
2 9 4 0  
3 0 0 0  
3 0 6 0  
3 1 2 0  
3 1 8 0  
US 7,138,253 B2 
60 
- con t inued  
actcgtagga caggtgccgg cagcgc tc tg  g g t c a t t t t c  ggcgaggacc g c t t t c g c t g  
gagcgcgacg atgatcggcc t g t c g c t t g c  gg ta t tcgga a t c t t g c a c g  ccc tcgc tca  
a g c c t t c g t c  ac tgg tcccg  ccaccaaacg t t t c g g c g a g  aagcaggcca t t a t c g c c g g  
catggcggcc ccacgggtgc gca tga tcg t  g c t c c t g t c g  t tgaggaccc ggctaggctg 
gcggggttgc c t t a c t g g t t  agcagaatga atcaccgata cgcgagcgaa cgtgaagcga 
c t g c t g c t g c  aaaacgtc tg cgacctgagc aacaacatga a t g g t c t t c g  g t t t c c g t g t  
t t c g t a a a g t  ctggaaacgc ggaagtcagc gccctgcacc a t t a t g t t c c  g g a t c t g c a t  
cgcaggatgc t g c t g g c t a c  cctgtggaac a c c t a c a t c t  g ta t taacga agcgctggca 
t t g a c c c t g a  g t g a t t t t t c  t c t g g t c c c g  ccgcatcca t  accgccagt t  g t t t a c c c t c  
acaacgt tcc agtaaccggg c a t g t t c a t c  atcagtaacc c g t a t c g t g a  g c a t c c t c t c  
t c g t t t c a t c  g g t a t c a t t a  cccccatgaa cagaaatccc cc t tacacgg aggcatcagt  
gaccaaacag gaaaaaaccg c c c t t a a c a t  g g c c c g c t t t  atcagaagcc agacat taac 
g c t t c t g g a g  aaactcaacg agctggacgc ggatgaacag gcagacatc t  g t g a a t c g c t  
tcacgaccac gctgatgagc t t t a c c g c a g  c tgcc tcgcg c g t t t c g g t g  atgacggtga 
aaacctc tga cacatgcagc tcccggagac ggtcacagct  t g t c t g t a a g  cggatgccgg 
gagcagacaa gcccgtcagg gcgcgtcagc gggtg t tggc  gggtgtcggg gcgcagccat 
gacccagtca cgtagcgata gcggagtgta t a c t g g c t t a  actatgcggc atcagagcag 
a t t g t a c t g a  gagtgcacca t a t a t g c g g t  gtgaaatacc gcacagatgc gtaaggagaa 
aataccgcat  caggcgctc t  t c c g c t t c c t  cgc tcac tga  c tcgc tgcgc  t c g g t c g t t c  
ggctgcggcg agcggtatca gctcactcaa aggcggtaat a c g g t t a t c c  acagaatcag 
gggataacgc aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa 
aggccgcgt t  g c t g g c g t t t  t t c c a t a g g c  tccgcccccc tgacgagcat  cacaaaaatc 
gacgctcaag tcagaggtgg cgaaacccga caggactata aagataccag g c g t t t c c c c  
c tggaagctc  cctcgtgcgc t c t c c t g t t c  cgaccctgcc gct taccgga t a c c t g t c c g  
c c t t t c t c c c  ttcgggaagc g t g g c g c t t t  c t c a t a g c t c  acgctgtagg t a t c t c a g t t  
cgg tg taggt  c g t t c g c t c c  aagctgggct  g tgtgcacga accccccgt t  cagcccgacc 
g c t g c g c c t t  a tccggtaac t a t c g t c t t g  agtccaaccc ggtaagacac g a c t t a t c g c  
cactggcagc agccactggt  aacaggatta gcagagcgag g ta tg taggc  ggtgctacag 
a g t t c t t g a a  g tgg tggcc t  aactacggct  acactagaag g a c a g t a t t t  g g t a t c t g c g  
c t c t g c t g a a  gccagt tacc t tcggaaaaa gagt tgg tag  c t c t t g a t c c  ggcaaacaaa 
ccaccgctgg tagcggtgg t  t t t t t t g t t t  gcaagcagca gat tacgcgc agaaaaaaag 
gatc tcaaga a g a t c c t t t g  a t c t t t t c t a  cggggtctga cgc tcagtgg  aacgaaaact 
cacgt taagg g a t t t t g g t c  atgaacaata a a a c t g t c t g  c t t a c a t a a a  cagtaataca 
aggggtg t ta  tgagccata t  tcaacgggaa a c g t c t t g c t  ctaggccgcg a t t a a a t t c c  
aacatggatg c t g a t t t a t a  tgggta taaa tgggctcgcg a t a a t g t c g g  gcaatcaggt  
gcgacaatct  a t c g a t t g t a  tgggaagccc gatgcgccag a g t t g t t t c t  gaaacatggc 
aaaggtagcg t t g c c a a t g a  t g t t a c a g a t  gagatggtca gactaaactg gctgacggaa 
t t t a t g c c t c  t t c c g a c c a t  c a a g c a t t t t  a t c c g t a c t c  c tga tga tgc  a t g g t t a c t c  
accactgcga tccccgggaa aacagcat tc  caggta t tag  aagaatatcc t g a t t c a g g t  
3 2 4 0  
3 3 0 0  
3 3 6 0  
3 4 2 0  
3 4 8 0  
3 5 4 0  
3 6 0 0  
3 6 6 0  
3 7 2 0  
3 7 8 0  
3 8 4 0  
3 9 0 0  
3 9 6 0  
4 0 2 0  
4 0 8 0  
4 1 4 0  
4 2 0 0  
4 2 6 0  
4 3 2 0  
4 3 8 0  
4 4 4 0  
4 5 0 0  
4 5 6 0  
4 6 2 0  
4 6 8 0  
4 7 4 0  
4 8 0 0  
4 8 6 0  
4 9 2 0  
4 9 8 0  
5 0 4 0  
5 1 0 0  
5 1 6 0  
5 2 2 0  
5 2 8 0  
5 3 4 0  
5 4 0 0  
5 4 6 0  
5 5 2 0  
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g a a a a t a t t g  t t g a t g c g c t  g g c a g t g t t c  c tgcgccggt  t g c a t t c g a t  t c c t g t t t g t  
a a t t g t c c t t  t t a a c a g c g a  t c g c g t a t t t  c g t c t c g c t c  aggcgcaa tc  a c g a a t g a a t  
a a c g g t t t g g  t t g a t g c g a g  t g a t t t t g a t  gacgagcgta  a tggc tggcc  t g t t g a a c a a  
g tc tggaaag  a a a t g c a t a a  a c t t t t g c c a  t t c t c a c c g g  a t t c a g t c g t  c a c t c a t g g t  
g a t t t c t c a c  t t g a t a a c c t  t a t t t t t g a c  gaggggaaat  t a a t a g g t t g  t a t t g a t g t t  
ggacgagtcg gaatcgcaga ccga taccag  g a t c t t g c c a  t c c t a t g g a a  c t g c c t c g g t  
g a g t t t t c t c  c t t c a t t a c a  g a a a c g g c t t  t t t c a a a a a t  a t g g t a t t g a  t a a t c c t g a t  
a t g a a t a a a t  t g c a g t t t c a  t t t g a t g c t c  g a t g a g t t t t  t c t a a g a a t t  a a t t c a t g a g  
c g g a t a c a t a  t t t g a a t g t a  t t t a g a a a a a  t a a a c a a a t a  ggggt tccgc  g c a c a t t t c c  
ccgaaaagtg  ccacc tgaaa  t t g t a a a c g t  t a a t a t t t t g  t t a a a a t t c g  c g t t a a a t t t  
t t g t t a a a t c  a g c t c a t t t t  t t a a c c a a t a  ggccgaaatc  ggcaaaa tcc  c t t a t a a a t c  
aaaagaa tag  accgagatag  g g t t g a g t g t  t g t t c c a g t t  tggaacaaga  g t c c a c t a t t  
aaagaacgtg  gac tccaacg  tcaaagggcg aaaaaccgtc  t a t c a g g g c g  a t g g c c c a c t  
acg tgaacca  t c a c c c t a a t  c a a g t t t t t t  ggggtcgagg t g c c g t a a a g  c a c t a a a t c g  
gaaccc taaa  gggagccccc g a t t t a g a g c  t tgacgggga  aagccggcga acgtggcgag 
aaaggaaggg aagaaagcga aaggagcggg cgctagggcg c t g g c a a g t g  t a g c g g t c a c  
gc tgcgcgta  accaccacac ccgccgcgct  t a a t g c g c c g  ctacagggcg c g t c c c a t t c  
gcca 
<210>  SEQ I D  NO 4 1  
<211>  LENGTH: 426  
<212>  TYPE: PRT 
<213>  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
<223>  OTHER INFORMATION: des igned  p r o t e i n  
<400>  SEQUENCE: 4 1  
M e t  Gly I l e  Glu Glu Gly Lys Leu Val I l e  Trp I l e  Asn Gly Asp Lys 
1 5 1 0  1 5  
Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr 
20  2 5  3 0  
Gly I l e  Lys Val Thr Val Glu H i s  P ro  Asp Lys Leu Glu Glu Lys Phe 
35  40 45 
Pro  Gln Val Ala Ala Thr Gly Asp Gly Pro  Asp I l e  I l e  Phe Trp Ala 
5 0  5 5  6 0  
H i s  Asp Arg Phe Gly Gly Tyr Ala Gln S e r  Gly Leu Leu Ala Glu I l e  
6 5  7 0  7 5  8 0  
Thr Pro  Asp Lys Ala Phe Gln Asp Lys Leu Tyr Pro  Phe Thr Trp Asp 
8 5  9 0  95  
Ala Val Arg Tyr Asn Gly Lys Leu I l e  Ala Tyr Pro  I l e  Ala Val G l u  
1 0 0  1 0 5  1 1 0  
Ala Leu S e r  Leu I l e  Tyr Asn Lys Asp Leu Leu Pro  Asn Pro  Pro  Lys 
1 1 5  1 2 0  1 2 5  
Thr Trp Glu Glu I l e  Pro  Ala Leu Asp Lys Glu Leu Lys Ala Lys G l y  
1 3 0  1 3 5  1 4 0  
Lys S e r  Ala Leu M e t  Phe Asn Leu Gln Glu Pro Tyr Phe Thr Trp Pro  
1 4 5  1 5 0  1 5 5  1 6 0  
Leu I l e  Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys 
1 6 5  1 7 0  1 7 5  
5 5 8 0  
5 6 4 0  
5 7 0 0  
5 7 6 0  
5 8 2 0  
5 8 8 0  
5 9 4 0  
6 0 0 0  
6 0 6 0  
6 1 2 0  
6 1 8 0  
6 2 4 0  
6 3 0 0  
6 3 6 0  
6 4 2 0  
6 4 8 0  
6 5 4 0  
6 5 4 4  
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T y r  A s p  I l e  L y s  A s p  V a l  G l y  V a l  A s p  A s n  A l a  G l y  A l a  L y s  A l a  G l y  
1 8 0  1 8 5  1 9 0  
L e u  T h r  Phe L e u  V a l  A s p  L e u  I l e  L y s  A s n  L y s  H i s  M e t  A s n  A l a  A s p  
1 9 5  2 0 0  2 0 5  
T h r  A s p  T y r  S e r  I l e  A l a  G l u  A l a  A l a  Phe A s n  L y s  G l y  G l u  T h r  A l a  
2 1 0  2 1 5  2 2 0  
M e t  T h r  I l e  A s n  G l y  P r o  T r p  A l a  T r p  S e r  A s n  I l e  A s p  T h r  S e r  L y s  
2 2 5  2 3 0  2 3 5  2 4 0  
V a l  A s n  T y r  G l y  V a l  T h r  V a l  L e u  P r o  T h r  Phe L y s  G l y  G l n  P r o  S e r  
2 4 5  2 5 0  2 5 5  
L y s  P r o  Phe V a l  G l y  V a l  L e u  S e r  A l a  G l y  I l e  A s n  A l a  A l a  S e r  P r o  
2 6 0  2 6 5  2 7 0  
A s n  L y s  G l u  L e u  A l a  L y s  G l u  Phe L e u  G l u  A s n  T y r  L e u  L e u  T h r  A s p  
2 7 5  2 8 0  2 8 5  
G l u  G l y  L e u  G l u  A l a  V a l  A s n  L y s  A s p  L y s  P ro  L e u  G l y  A l a  V a l  A l a  
2 9 0  2 9 5  3 0 0  
L e u  L y s  S e r  T y r  G l u  G l u  G l u  L e u  A l a  L y s  A s p  P r o  A r g  I l e  A l a  A l a  
3 0 5  3 1 0  3 1 5  3 2 0  
T h r  M e t  G l u  A s n  A l a  G l n  L y s  G l y  G l u  I l e  M e t  P r o  A s n  I l e  P r o  G l n  
3 2 5  3 3 0  3 3 5  
M e t  S e r  A l a  Phe T r p  T y r  A l a  V a l  A r g  T h r  A l a  V a l  I l e  A s n  A l a  A l a  
3 4 0  3 4 5  3 5 0  
S e r  G l y  A r g  G l n  T h r  V a l  A s p  G l u  A l a  L e u  L y s  A s p  A l a  G l n  T h r  A s n  
3 5 5  3 6 0  3 6 5  
S e r  S e r  S e r  G l y  G l y  S e r  G l y  S e r  G l y  M e t  A s p  G l u  L y s  T h r  T h r  G l y  
3 7 0  3 7 5  3 8 0  
T r p  A r g  G l y  G l y  H i s  V a l  V a l  G l u  G l y  L e u  A l a  G l y  G l u  L e u  G l u  G l n  
3 8 5  3 9 0  3 9 5  400  
L e u  A r g  A l a  A r g  L e u  G l u  H i s  H i s  P r o  G l n  G l y  G l n  A r g  G l u  P r o  G l y  
4 0 5  410  4 1 5  
S e r  G l y  H i s  H i s  H i s  H i s  H i s  H i s  G l u  Phe 
420  4 2 5  
What is claimed is: 
1. A purified nucleic acid encoding a peptide that binds 45 constant is less than 50 nM. 
constant is less than 10 nM. 
7. The nucleic acid of claim 6, wherein said dissociation 
8, The nucleic acid of claim 3, wherein said dissociation 
9. The nucleic acid of claim 8, wherein said dissociation 
10. The nucleic acid of claim 1, wherein said peptide 
comprises an amino acid sequence having at least 90% 
sequence identity to the first 38 amino acids of SEQ ID 
NO:25, 
11. The nUCleiC acid of claim 10, wherein said peptide 
comprises an amino acid sequence having at least 95% 
sequence identity to the first 38 amino acids of SEQ ID 
NO:25. 
12, ne nucleic acid of claim 11, wherein said peptide 
comprises the amino acid sequence of at least the first 38 
amino acids of SEQ ID NO:25, 
13. The nucleic acid of claim 2, wherein said peptide 
65 comprises an amino acid sequence having at least 90% 
sequence identity to the first 38 amino acids of SEQ ID 
NO:25. 
streptavidin with a dissociation constant less than 10 pM and 
comprises an amino acid sequence having at least 80% 
identity to the first 38 amino acids of SEQ ID NO:25, 
wherein said peptide is not disulfide bonded or cyclized. 
streptavidin with a dissociation constant less than 10 pM and 
comprises an amino acid sequence having at least 80% 
identity to the first 38 amino acids of SEQ ID NO:25, 
wherein the amino acid sequence of said peptide does not 
contain a Histidine-Proline-Glutamine (HPQ), Histidine- 55 
Proline-Methionine (HPM), Histidine-Proline-Asparagine 
(HPN), or Histidine-Glutamine-Proline (HQP) motif. 
3. A purified nucleic acid encoding a peptide that binds 
streptavidin with a dissociation constant less than 23 nM and 
comprises an amino acid sequence having at least 80% 60 
identity to the first 38 amino acids of SEQ ID NO:25. 
4. The nucleic acid of claim 1 or 2, wherein said disso- 
ciation constant is less than 5 pM. 
5, The nucleic acid of claim or 2, wherein said disso- 
ciation constant is less than 1 pM. 
6. The nucleic acid of claim 5, wherein said dissociation 
constant is less than 100 nM. 
2. A purified nucleic acid encoding a peptide that binds 50 constant is less than 5 nM. 
US 7,138,253 B2 
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14. The nucleic acid of claim 2, wherein said peptide 19. The nucleic acid of claim 18, wherein said peptide is 
comprises an amino acid sequence having at least 95% attached to the amino terminus or the carboxy terminus of 
sequence identity to the first 38 amino acids of SEQ ID said protein of interest, or wherein said peptide is positioned 
NO:25. between the amino and carboxy termini of said protein of 
15. The nucleic acid of claim 3, wherein said peptide 5 interest. 
comprises an amino acid sequence having at least 90% 20, The nucleic acid of claim 18, wherein said peptide is 
sequence identity to the first 38 amino acids of SEQ ID linked to said protein of interest by a linker comprising a 
NO:25. protease-sensitive site. 
16. The nucleic acid of claim 3, wherein said peptide 21, The nucleic acid of claim 18, wherein said peptide of 
comprises an amino acid sequence having at least 95% i o  (a), (b), or (c) comprises an amino acid sequence having at 
NO:25. 
1-3. 
a protein of interest covalently linked to: 
sequence identity to the first 38 amino acids Of SEQ ID least 90% sequence identity to the first 38 amino acids of 
SEQ ID NO:25. 
17. A vector comprising a nucleic acid of any of claims 
22. The nucleic acid of claim 21, wherein said peptide of 
least 95% sequence identity to the first 38 amino acids of 
SEQ ID NO:25. 
23. The nucleic acid of claim 22, wherein said peptide of 
(a), (b), Or (C) comprises the amino acid sequence ofthe first 
18, A nucleic acid encoding a fusion protein comprising 15 (a), (b), Or ('1 comprises an amino acid sequence having at 
(a) a peptide which binds streptavidin with a dissociation 
constant less than 10 p~ and comprises an amino acid 
sequence having at least 80% identity to the first 38 
amino acids of SEQ ID NO:25, wherein said peptide is 20 38 amino acids of SEQ ID IKk25. 
not disulfide bonded or cyclized; 
(b) a peptide which binds streptavidin with a dissociation 
constant less than 10 pM and comprises an amino acid 
sequence having at least 80% identity to the first 38 
amino acids of SEQ ID NO:25, wherein said peptide 25 
does not contain an HPQ, HPM, HPN, or HQP motif; 
or 
(c) a peptide which binds streptavidin with a dissociation 
constant less than 23 nM and comprises an amino acid 
sequence having at least 80% identity to the first 38 30 
24. A vector comprising a nucleic acid of claim 18. 
25, A method of producing a streptavidin-binding fusion 
(a) expressing in a host cell, a gene encoding a fusion 
protein of claim 18; and 
(b) culturing said host cell under conditions appropriate 
for production of said fusion protein; and 
(C) Purifying said fusion Protein from said cell. 
protein, said method comprising the steps of: 
amino acids of SEQ ID NO:25. * * * * *  
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Fig. 6A (continued) 
(SEQ ID No.:38) 
M G I E E G K L V I W I N G D K G Y N G L ~ V G K K F E K D T G I K V T V E H T G ~ G F D I  z EWAHDRFGGYAQSGLLAE I 
T P D K A F Q D X L Y P F T W D A V R Y N G K L I A Y P I A V E A I r S L I Y N L ~ E F Y F ~ W F  
L1AADGGYAFKYENGKYDJ:KDVGVDNAGAKAGLTFLVDLIKNKHMNqDTDYSIAEAAFNKGETAMTINGPWAWSNI.DTSK 
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEEL~DPRr~ 
TMENAQKGEIMPNIPQMSAFA~TATJINAASGRQTVDEALKDAQTNSSSGGSG~GMDEKTTGW~GGH~GL~G~~EQ 
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(SEQ ID No. :39) 
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(SEQ ID No.:4l) z 
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